[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuLTGF3IlyC42HBxFF5d9WqYKKLgtKAOBxiCH4rmwljs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":60,"rows":67},"Galderma R&D",[4],279,false,14,67,62369,3,113,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Acne Vulgaris",32,{"name":18,"count":19},"Rosacea",19,{"name":21,"count":22},"Acne",11,{"name":24,"count":25},"Glabellar Frown Lines",9,{"name":27,"count":28},"Atopic Dermatitis",7,{"name":30,"count":28},"Plaque Psoriasis",{"name":32,"count":33},"Prurigo Nodularis",6,{"name":35,"count":33},"Psoriasis",[37,42,47,51,56],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03989206","Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis","2026-08-31","Nemolizumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07074977","Proof of Concept Study to Assess the Pharmacokinetics\u002FPharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","2026-09","nemolizumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":41},"NCT04204616","A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","2026-10-26",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07186413","A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg\u002Fg Cream in Chinese Subjects With Acne Vulgaris","2026-12-31","Trifarotene",{"nctId":57,"briefTitle":58,"date":59,"intervention":41},"NCT07047690","A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis","2028-05-28",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,235,284,311,371,422,470,518,563,595,631,667,694,728,762,791,825,847,882,904,929,963,987,1011,1035,1053,1071,1096,1114,1132,1150,1168,1186,1211,1229,1253,1277,1295,1313,1331,1355,1373,1391,1413,1436,1458,1483,1501,1524,1550,1568,1586,1610,1633,1654,1678,1703,1721,1747,1765,1789,1813,1838,1856,1879,1897,1922,1940,1963,1987,2005,2027,2045,2063,2081,2106,2124,2148,2171,2189,2210,2233,2281,2324,2365,2400,2447,2469,2505,2542,2569,2602,2624,2652,2684,2708,2733,2751,2775,2799,2823,2841,2864,2882,2905,2930,2948,2966,2984,3010,3028,3046,3069,3087,3105,3131,3149,3167,3185,3209,3227,3245,3270,3288,3312,3337,3355,3373,3391,3415,3433,3457,3475,3493,3518,3536,3559,3587,3605,3623,3641,3659,3677,3695,3720,3738,3760,3778,3796,3834,3864,3898,3922,3940,3958,3976,3994,4012,4030,4054,4080,4098,4116,4134,4152,4170,4188,4212,4230,4248,4272,4290,4315,4333,4359,4377,4395,4418,4436,4462,4480,4498,4516,4534,4552,4577,4595,4618,4636,4660,4678,4702,4730,4748,4766,4784,4802,4820,4838,4856,4874,4897,4921,4939,4957,5000,5027,5051,5076,5094,5117,5141,5159],{"intervention":41,"totalTrials":69,"cells":70},16,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":88,"PHASE3":157,"PHASE4":231,"NA":233},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[76],{"nctId":77,"briefTitle":78,"status":79,"phases":80,"primaryCompletion":81,"completion":82,"start":83,"enrollment":84,"conditions":85,"interventions":87},"NCT05405985","Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe","COMPLETED",[62],"2022-11-11","2022-12-08","2022-08-11",192,[86],"Healthy Volunteers",[41,41],{"trials":89,"activeCount":156,"soonestReadout":45},[90,100,110,119,129,139,148],{"nctId":91,"briefTitle":92,"status":79,"phases":93,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT04562116","A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis",[63],"2023-06-07","2021-12-08",17,[27],[41,99],"CYP 450 Substrates",{"nctId":101,"briefTitle":102,"status":79,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT04921345","Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis",[63],"2025-04-28","2021-09-23",109,[108],"Moderate-to-Severe Atopic Dermatitis",[41,41],{"nctId":57,"briefTitle":58,"status":111,"phases":112,"primaryCompletion":59,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"RECRUITING",[63],"2028-07-23","2026-02-20",162,[117],"Systemic Sclerosis",[41],{"nctId":120,"briefTitle":121,"status":79,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":128},"NCT03100344","Dose-ranging Study of Nemolizumab in Atopic Dermatitis",[63],"2018-07-19","2018-09-21","2017-06-14",226,[27],[41],{"nctId":130,"briefTitle":131,"status":79,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT04365387","A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab",[63],"2023-07-07","2020-03-05",242,[137],"Dermatitis, Atopic",[41],{"nctId":140,"briefTitle":141,"status":79,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT03921411","A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)",[63],"2020-08-19","2019-04-09",20,[27],[41],{"nctId":43,"briefTitle":44,"status":111,"phases":149,"primaryCompletion":45,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},[63],"2027-01","2025-10-20",50,[154],"Chronic Pruritus of Unknown Origin",[46],2,{"trials":158,"activeCount":156,"soonestReadout":40},[159,168,175,185,194,204,214,225],{"nctId":160,"briefTitle":161,"status":79,"phases":162,"primaryCompletion":163,"completion":83,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT03985943","Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis",[64],"2021-12-29","2019-06-27",941,[108],[41],{"nctId":38,"briefTitle":39,"status":169,"phases":170,"primaryCompletion":40,"completion":40,"start":171,"enrollment":172,"conditions":173,"interventions":174},"ACTIVE_NOT_RECRUITING",[64],"2019-12-30",1700,[108],[41],{"nctId":176,"briefTitle":177,"status":79,"phases":178,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":184},"NCT03989349","Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis",[64],"2022-02-23","2022-09-26","2019-06-30",787,[108],[41],{"nctId":186,"briefTitle":187,"status":79,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":193},"NCT05052983","A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis",[64],"2023-09-11","2022-01-24",34,[32],[41],{"nctId":195,"briefTitle":196,"status":79,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":203},"NCT04501679","A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)",[64],"2022-03-30","2022-03-31","2020-08-11",274,[32],[41],{"nctId":205,"briefTitle":206,"status":79,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT05075408","To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus",[63,64],"2024-01-04","2022-03-18",258,[212],"Chronic Kidney Disease Associated Moderate to Severe Pruritus",[41,41],{"nctId":215,"briefTitle":216,"status":217,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":73,"conditions":221,"interventions":223},"NCT05056779","Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable","WITHDRAWN",[64],"2023-07","2023-01",[222],"Moderate-to-severe Atopic Dermatitis",[41,224],"CD14152 placebo",{"nctId":48,"briefTitle":49,"status":169,"phases":226,"primaryCompletion":50,"completion":50,"start":227,"enrollment":228,"conditions":229,"interventions":230},[64],"2021-01-11",500,[32],[41],{"trials":232,"activeCount":73},[],{"trials":234,"activeCount":73},[],{"intervention":236,"totalTrials":11,"cells":237},"Vehicle cream",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":258,"PHASE4":280,"NA":282},{"trials":239,"activeCount":73},[],{"trials":241,"activeCount":73},[],{"trials":243,"activeCount":73},[244],{"nctId":245,"briefTitle":246,"status":79,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT01616654","Dose Range Study of CD5789 in Acne Vulgaris",[63],"2013-07-24","2014-06-12","2012-06-20",304,[15],[254,255,256,257,236],"CD5789 25 µg\u002Fg cream","CD5789 50 µg\u002Fg cream","CD5789 100 µg\u002Fg cream","Tazarotene 0.1% gel",{"trials":259,"activeCount":279,"soonestReadout":54},[260,267],{"nctId":52,"briefTitle":53,"status":111,"phases":261,"primaryCompletion":54,"completion":54,"start":262,"enrollment":263,"conditions":264,"interventions":265},[64],"2025-09-23",561,[15],[55,266],"Vehicle Cream",{"nctId":268,"briefTitle":269,"status":270,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT04269395","A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study","TERMINATED",[64],"2021-09-01","2020-04-07",125,[276],"Keratosis, Actinic",[278,236],"MAL Cream",1,{"trials":281,"activeCount":73},[],{"trials":283,"activeCount":73},[],{"intervention":55,"totalTrials":156,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":307,"NA":309},{"trials":287,"activeCount":73},[],{"trials":289,"activeCount":73},[],{"trials":291,"activeCount":73},[],{"trials":293,"activeCount":279,"soonestReadout":54},[294,298],{"nctId":52,"briefTitle":53,"status":111,"phases":295,"primaryCompletion":54,"completion":54,"start":262,"enrollment":263,"conditions":296,"interventions":297},[64],[15],[55,266],{"nctId":299,"briefTitle":300,"status":79,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT03915860","Participant Reported Outcomes With Use of Trifarotene 50 μg\u002Fg Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris",[64],"2019-12-23","2019-03-27",47,[15],[55],{"trials":308,"activeCount":73},[],{"trials":310,"activeCount":73},[],{"intervention":312,"totalTrials":313,"cells":314},"Adapalene\u002FBenzoyl Peroxide",4,{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":357,"NA":369},{"trials":316,"activeCount":73},[],{"trials":318,"activeCount":73},[],{"trials":320,"activeCount":73},[],{"trials":322,"activeCount":73},[323,332,344],{"nctId":324,"briefTitle":325,"status":79,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT00446043","Long-term Study of Efficacy\u002FSafety of Adapalene\u002FBenzoyl Peroxide Topical Gel in Acne Vulgaris Subjects",[64],"2005-05-23","2004-02-17",452,[15],[312],{"nctId":333,"briefTitle":334,"status":79,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":340},"NCT00422240","Study to Demonstrate the Efficacy and Safety of Adapalene\u002FBenzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris",[64],"2007-07-12","2006-06-27",1668,[15],[312,341,342,343],"Adapalene Gel, 0.1%","Benzoyl Peroxide Gel 2.5%","Gel Vehicle",{"nctId":345,"briefTitle":346,"status":79,"phases":347,"primaryCompletion":348,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":353},"NCT00421993","A Study to Demonstrate the Efficacy and Safety of Adapalene\u002FBenzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris",[64],"2007-10","2007-12","2006-10",1670,[15],[312,354,355,356],"Adapalene","Benzoyl Peroxide","Topical Gel Vehicle",{"trials":358,"activeCount":73},[359],{"nctId":360,"briefTitle":361,"status":79,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":367},"NCT01138735","Epiduo Pediatric Acne Study",[65],"2011-08","2010-06",285,[21],[368,356],"adapalene\u002Fbenzoyl peroxide",{"trials":370,"activeCount":73},[],{"intervention":372,"totalTrials":313,"cells":373},"Azelaic acid 15% Gel",{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":401,"NA":420},{"trials":375,"activeCount":73},[],{"trials":377,"activeCount":73},[],{"trials":379,"activeCount":73},[],{"trials":381,"activeCount":73},[382,394],{"nctId":383,"briefTitle":384,"status":79,"phases":385,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT01493687","Phase 3 Papulopustular Rosacea Study",[64],"2013-07","2013-08","2011-12",683,[391],"Papulopustular Rosacea (PPR)",[393,372],"CD5024",{"nctId":395,"briefTitle":384,"status":79,"phases":396,"primaryCompletion":387,"completion":387,"start":388,"enrollment":397,"conditions":398,"interventions":400},"NCT01494467",[64],688,[399],"Papulopustular Rosacea",[393,372],{"trials":402,"activeCount":73},[403,413],{"nctId":404,"briefTitle":405,"status":79,"phases":406,"primaryCompletion":364,"completion":364,"start":364,"enrollment":407,"conditions":408,"interventions":410},"NCT01139008","Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin",[65],80,[409],"Skin Manifestations",[411,412],"metronidazole 1% gel","azelaic acid 15% gel",{"nctId":414,"briefTitle":415,"status":79,"phases":416,"primaryCompletion":364,"completion":364,"start":364,"enrollment":417,"conditions":418,"interventions":419},"NCT01139047","Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin",[65],77,[409],[411,412],{"trials":421,"activeCount":73},[],{"intervention":423,"totalTrials":11,"cells":424},"Vehicle Gel",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":442,"PHASE4":454,"NA":468},{"trials":426,"activeCount":73},[],{"trials":428,"activeCount":73},[],{"trials":430,"activeCount":73},[431],{"nctId":432,"briefTitle":433,"status":79,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":440},"NCT01174030","Efficacy and Safety Study of CD07805\u002F47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea",[63],"2010-12","2011-01","2010-08",269,[18],[441,423,441,441,423],"CD07805\u002F47 Gel",{"trials":443,"activeCount":73},[444],{"nctId":445,"briefTitle":446,"status":79,"phases":447,"primaryCompletion":448,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT00687908","Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance",[64],"2009-07","2008-11",243,[21],[453,423],"Adapalene 0.1% \u002F Benzoyl Peroxide 2.5% Gel",{"trials":455,"activeCount":73},[456],{"nctId":457,"briefTitle":458,"status":79,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":9,"conditions":463,"interventions":465},"NCT02735421","Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars",[65],"2017-06-05","2017-11-23","2016-05-13",[15,464],"Atrophic Acne Scars",[466,467],"ABPO Forte Gel","Vehicle gel",{"trials":469,"activeCount":73},[],{"intervention":471,"totalTrials":11,"cells":472},"Trifarotene Cream",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":516},{"trials":474,"activeCount":73},[],{"trials":476,"activeCount":73},[],{"trials":478,"activeCount":73},[],{"trials":480,"activeCount":73},[],{"trials":482,"activeCount":73},[483,496,506],{"nctId":484,"briefTitle":485,"status":79,"phases":486,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":491},"NCT04451330","A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)",[65],"2021-04-26","2020-07-29",202,[15],[492,493,494,495],"Trifarotene cream","Doxycycline hyclate","Trifarotene Vehicle","Doxycycline Placebo",{"nctId":497,"briefTitle":498,"status":79,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":504},"NCT05089708","AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation",[65],"2022-12-15","2021-12-22",123,[15],[471,505],"Trifarotene Vehicle Cream",{"nctId":507,"briefTitle":508,"status":79,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":515},"NCT04856904","Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation",[65],"2023-02-08","2023-06-30","2021-05-28",121,[15],[471,505],{"trials":517,"activeCount":73},[],{"intervention":519,"totalTrials":11,"cells":520},"Ivermectin 1% cream",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":539,"NA":561},{"trials":522,"activeCount":73},[],{"trials":524,"activeCount":73},[],{"trials":526,"activeCount":73},[],{"trials":528,"activeCount":73},[529],{"nctId":530,"briefTitle":531,"status":79,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":537},"NCT01493947","CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study",[64],"2013-12","2012-04",962,[399],[519,538],"Metronidazole 0.75% cream",{"trials":540,"activeCount":73},[541,551],{"nctId":542,"briefTitle":543,"status":79,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":549},"NCT03075891","Oracea Soolantra Association in Participants With Severe Rosacea",[65],"2018-02-08","2017-07-05",273,[18],[519,550],"Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads)",{"nctId":552,"briefTitle":553,"status":79,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":559},"NCT02616250","MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.",[65],"2016-09","2015-12",190,[18],[560,519],"Brimonidine 0.33% gel",{"trials":562,"activeCount":73},[],{"intervention":356,"totalTrials":11,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":587,"NA":593},{"trials":566,"activeCount":73},[],{"trials":568,"activeCount":73},[],{"trials":570,"activeCount":73},[],{"trials":572,"activeCount":73},[573,583],{"nctId":574,"briefTitle":575,"status":79,"phases":576,"primaryCompletion":577,"completion":577,"start":386,"enrollment":578,"conditions":579,"interventions":580},"NCT01880320","Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%\u002FCD1579 2.5 % Topical Gel in Acne Vulgaris",[64],"2014-03",503,[15],[581,582,356],"CD0271 0.3% \u002F CD1579 2.5%","CD0271 0.1% \u002F CD1579 2.5%",{"nctId":345,"briefTitle":346,"status":79,"phases":584,"primaryCompletion":348,"completion":349,"start":350,"enrollment":351,"conditions":585,"interventions":586},[64],[15],[312,354,355,356],{"trials":588,"activeCount":73},[589],{"nctId":360,"briefTitle":361,"status":79,"phases":590,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":591,"interventions":592},[65],[21],[368,356],{"trials":594,"activeCount":73},[],{"intervention":354,"totalTrials":11,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":612,"PHASE4":618,"NA":629},{"trials":598,"activeCount":73},[],{"trials":600,"activeCount":73},[],{"trials":602,"activeCount":73},[603],{"nctId":604,"briefTitle":605,"status":79,"phases":606,"primaryCompletion":534,"completion":607,"start":608,"enrollment":145,"conditions":609,"interventions":611},"NCT01213199","Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars",[63],"2012-09","2011-03",[610],"Acne Scars",[354],{"trials":613,"activeCount":73},[614],{"nctId":345,"briefTitle":346,"status":79,"phases":615,"primaryCompletion":348,"completion":349,"start":350,"enrollment":351,"conditions":616,"interventions":617},[64],[15],[312,354,355,356],{"trials":619,"activeCount":73},[620],{"nctId":621,"briefTitle":622,"status":79,"phases":623,"primaryCompletion":624,"completion":449,"start":625,"enrollment":626,"conditions":627,"interventions":628},"NCT00660985","Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%",[65],"2008-08","2008-05",51,[15],[354,354],{"trials":630,"activeCount":73},[],{"intervention":632,"totalTrials":156,"cells":633},"clobetasol propionate spray 0.05%",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":652,"NA":665},{"trials":635,"activeCount":73},[],{"trials":637,"activeCount":73},[],{"trials":639,"activeCount":73},[],{"trials":641,"activeCount":73},[642],{"nctId":643,"briefTitle":644,"status":79,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":650},"NCT00658788","Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis",[64],"2009-01","2008-03",305,[35],[632,651],"calcitriol ointment",{"trials":653,"activeCount":73},[654],{"nctId":655,"briefTitle":656,"status":79,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT00881868","Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp",[65],"2009-12","2009-04",81,[662],"Scalp Psoriasis",[632,664],"Vehicle spray",{"trials":666,"activeCount":73},[],{"intervention":651,"totalTrials":156,"cells":668},{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":681,"NA":692},{"trials":670,"activeCount":73},[],{"trials":672,"activeCount":73},[],{"trials":674,"activeCount":73},[],{"trials":676,"activeCount":73},[677],{"nctId":643,"briefTitle":644,"status":79,"phases":678,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":679,"interventions":680},[64],[35],[632,651],{"trials":682,"activeCount":73},[683],{"nctId":684,"briefTitle":685,"status":79,"phases":686,"primaryCompletion":687,"completion":688,"start":689,"enrollment":19,"conditions":690,"interventions":691},"NCT02186665","Plaque Psoriasis Study in Pediatric Subjects",[65],"2015-11","2016-01","2014-07",[30],[651],{"trials":693,"activeCount":73},[],{"intervention":695,"totalTrials":156,"cells":696},"Epiduo gel",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":726},{"trials":698,"activeCount":73},[],{"trials":700,"activeCount":73},[],{"trials":702,"activeCount":73},[],{"trials":704,"activeCount":73},[],{"trials":706,"activeCount":73},[707,716],{"nctId":708,"briefTitle":709,"status":79,"phases":710,"primaryCompletion":437,"completion":437,"start":711,"enrollment":712,"conditions":713,"interventions":714},"NCT01188538","Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel",[65],"2010-03",40,[15],[695,715],"BPO",{"nctId":717,"briefTitle":718,"status":79,"phases":719,"primaryCompletion":720,"completion":720,"start":534,"enrollment":721,"conditions":722,"interventions":723},"NCT01522456","Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel",[65],"2012-05",73,[15],[724,725],"Epiduo Gel","Retin-A Micro Microsphere 0.1%",{"trials":727,"activeCount":73},[],{"intervention":729,"totalTrials":156,"cells":730},"adapalene gel, 0.3%",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":750,"NA":760},{"trials":732,"activeCount":73},[],{"trials":734,"activeCount":73},[],{"trials":736,"activeCount":73},[],{"trials":738,"activeCount":73},[739],{"nctId":740,"briefTitle":741,"status":79,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT00647556","Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage",[64],"2010-01","2008-04",30,[747],"Photoaging",[729,749],"tretinoin 0.05% emollient cream",{"trials":751,"activeCount":73},[752],{"nctId":753,"briefTitle":754,"status":79,"phases":755,"primaryCompletion":624,"completion":624,"start":349,"enrollment":756,"conditions":757,"interventions":758},"NCT00671749","Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin\u002FBenzoyl Peroxide Gel) in Subjects With Acne Vulgaris",[65],100,[15],[729,759],"clindamycin\u002Fbenzoyl peroxide gel",{"trials":761,"activeCount":73},[],{"intervention":341,"totalTrials":156,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":776,"NA":789},{"trials":765,"activeCount":73},[],{"trials":767,"activeCount":73},[],{"trials":769,"activeCount":73},[],{"trials":771,"activeCount":73},[772],{"nctId":333,"briefTitle":334,"status":79,"phases":773,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":774,"interventions":775},[64],[15],[312,341,342,343],{"trials":777,"activeCount":73},[778],{"nctId":779,"briefTitle":780,"status":79,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":786},"NCT00469755","Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne",[65],"2006-09","2006-02",302,[15],[341,787,788],"Tazarotene Cream, 0.1%","Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%",{"trials":790,"activeCount":73},[],{"intervention":792,"totalTrials":156,"cells":793},"Azzalure",{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":823},{"trials":795,"activeCount":73},[],{"trials":797,"activeCount":73},[],{"trials":799,"activeCount":73},[],{"trials":801,"activeCount":73},[],{"trials":803,"activeCount":73},[804,814],{"nctId":805,"briefTitle":806,"status":79,"phases":807,"primaryCompletion":808,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":813},"NCT02297503","Safety and Efficacy of Treatment With Azzalure, Restylane\u002FEmervel Filler and Restylane Skinbooster",[65],"2016-12","2014-11",61,[812],"Facial Aesthetic Treatment",[792],{"nctId":815,"briefTitle":816,"status":79,"phases":817,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT02108158","A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines",[65],"2014-12","2014-04",62,[24],[792],{"trials":824,"activeCount":73},[],{"intervention":411,"totalTrials":156,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":845},{"trials":828,"activeCount":73},[],{"trials":830,"activeCount":73},[],{"trials":832,"activeCount":73},[],{"trials":834,"activeCount":73},[],{"trials":836,"activeCount":73},[837,841],{"nctId":404,"briefTitle":405,"status":79,"phases":838,"primaryCompletion":364,"completion":364,"start":364,"enrollment":407,"conditions":839,"interventions":840},[65],[409],[411,412],{"nctId":414,"briefTitle":415,"status":79,"phases":842,"primaryCompletion":364,"completion":364,"start":364,"enrollment":417,"conditions":843,"interventions":844},[65],[409],[411,412],{"trials":846,"activeCount":73},[],{"intervention":848,"totalTrials":156,"cells":849},"Cetaphil",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":880},{"trials":851,"activeCount":73},[],{"trials":853,"activeCount":73},[],{"trials":855,"activeCount":73},[],{"trials":857,"activeCount":73},[],{"trials":859,"activeCount":73},[860,871],{"nctId":861,"briefTitle":862,"status":79,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":16,"conditions":866,"interventions":870},"NCT07398989","A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin",[65],"2026-03-25","2025-08-12",[867,868,869],"Crepey Skin","Aging Skin","Photo-aged Skin",[848],{"nctId":872,"briefTitle":873,"status":79,"phases":874,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT06357221","A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients",[65],"2024-07-18","2024-04-08",46,[30,35],[848],{"trials":881,"activeCount":73},[],{"intervention":505,"totalTrials":156,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":902},{"trials":885,"activeCount":73},[],{"trials":887,"activeCount":73},[],{"trials":889,"activeCount":73},[],{"trials":891,"activeCount":73},[],{"trials":893,"activeCount":73},[894,898],{"nctId":497,"briefTitle":498,"status":79,"phases":895,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":896,"interventions":897},[65],[15],[471,505],{"nctId":507,"briefTitle":508,"status":79,"phases":899,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":900,"interventions":901},[65],[15],[471,505],{"trials":903,"activeCount":73},[],{"intervention":355,"totalTrials":156,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":918,"NA":927},{"trials":907,"activeCount":73},[],{"trials":909,"activeCount":73},[],{"trials":911,"activeCount":73},[],{"trials":913,"activeCount":73},[914],{"nctId":345,"briefTitle":346,"status":79,"phases":915,"primaryCompletion":348,"completion":349,"start":350,"enrollment":351,"conditions":916,"interventions":917},[64],[15],[312,354,355,356],{"trials":919,"activeCount":73},[920],{"nctId":921,"briefTitle":922,"status":79,"phases":923,"primaryCompletion":688,"completion":688,"start":924,"enrollment":152,"conditions":925,"interventions":926},"NCT02589405","Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris",[65],"2015-08",[15],[355],{"trials":928,"activeCount":73},[],{"intervention":930,"totalTrials":156,"cells":931},"Doxycycline",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":961},{"trials":933,"activeCount":73},[],{"trials":935,"activeCount":73},[],{"trials":937,"activeCount":73},[],{"trials":939,"activeCount":73},[],{"trials":941,"activeCount":73},[942,951],{"nctId":943,"briefTitle":944,"status":79,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":950},"NCT01308619","Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo",[65],"2012-08","2011-04",170,[18],[930],{"nctId":952,"briefTitle":953,"status":79,"phases":954,"primaryCompletion":955,"completion":955,"start":956,"enrollment":957,"conditions":958,"interventions":959},"NCT01426269","Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo",[65],"2013-06","2011-09",235,[18],[930,960],"Metronidazole",{"trials":962,"activeCount":73},[],{"intervention":964,"totalTrials":279,"cells":965},"Adapalene\u002Fbenzoyl peroxide gel, 0.1%\u002F2.5%",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":985},{"trials":967,"activeCount":73},[],{"trials":969,"activeCount":73},[],{"trials":971,"activeCount":73},[],{"trials":973,"activeCount":73},[],{"trials":975,"activeCount":73},[976],{"nctId":977,"briefTitle":978,"status":79,"phases":979,"primaryCompletion":980,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":984},"NCT02249104","A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris",[65],"2015-02","2014-08",28,[15],[964],{"trials":986,"activeCount":73},[],{"intervention":988,"totalTrials":279,"cells":989},"Facial Cleanser and Moisturizer SPF 30",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":996,"PHASE4":998,"NA":1009},{"trials":991,"activeCount":73},[],{"trials":993,"activeCount":73},[],{"trials":995,"activeCount":73},[],{"trials":997,"activeCount":73},[],{"trials":999,"activeCount":73},[1000],{"nctId":1001,"briefTitle":1002,"status":79,"phases":1003,"primaryCompletion":955,"completion":955,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1008},"NCT01909713","Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.",[65],"2013-05",35,[1007],"Acne Prone Skin",[988],{"trials":1010,"activeCount":73},[],{"intervention":1012,"totalTrials":279,"cells":1013},"Vectical™ Ointment weekdays and Clobex® Spray weekends regimen",{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1033},{"trials":1015,"activeCount":73},[],{"trials":1017,"activeCount":73},[],{"trials":1019,"activeCount":73},[],{"trials":1021,"activeCount":73},[],{"trials":1023,"activeCount":73},[1024],{"nctId":1025,"briefTitle":1026,"status":79,"phases":1027,"primaryCompletion":711,"completion":711,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1031},"NCT00988637","Evaluate Safety\u002FEfficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis",[65],"2009-10",138,[30],[1012,1032],"Clobex® Spray morning and Vectical™ Ointment evening regimen",{"trials":1034,"activeCount":73},[],{"intervention":1032,"totalTrials":279,"cells":1036},{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1051},{"trials":1038,"activeCount":73},[],{"trials":1040,"activeCount":73},[],{"trials":1042,"activeCount":73},[],{"trials":1044,"activeCount":73},[],{"trials":1046,"activeCount":73},[1047],{"nctId":1025,"briefTitle":1026,"status":79,"phases":1048,"primaryCompletion":711,"completion":711,"start":1028,"enrollment":1029,"conditions":1049,"interventions":1050},[65],[30],[1012,1032],{"trials":1052,"activeCount":73},[],{"intervention":466,"totalTrials":279,"cells":1054},{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1069},{"trials":1056,"activeCount":73},[],{"trials":1058,"activeCount":73},[],{"trials":1060,"activeCount":73},[],{"trials":1062,"activeCount":73},[],{"trials":1064,"activeCount":73},[1065],{"nctId":457,"briefTitle":458,"status":79,"phases":1066,"primaryCompletion":460,"completion":461,"start":462,"enrollment":9,"conditions":1067,"interventions":1068},[65],[15,464],[466,467],{"trials":1070,"activeCount":73},[],{"intervention":1072,"totalTrials":279,"cells":1073},"Loceryl NL + Cosmetic varnish",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1094},{"trials":1075,"activeCount":73},[],{"trials":1077,"activeCount":73},[],{"trials":1079,"activeCount":73},[],{"trials":1081,"activeCount":73},[],{"trials":1083,"activeCount":73},[1084],{"nctId":1085,"briefTitle":1086,"status":79,"phases":1087,"primaryCompletion":688,"completion":688,"start":1088,"enrollment":152,"conditions":1089,"interventions":1091},"NCT02321098","Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish",[65],"2014-02",[1090],"Foot Dermatoses",[1072,1092,1093],"Loceryl NL 12 weeks","Loceryl NL 15 months",{"trials":1095,"activeCount":73},[],{"intervention":1092,"totalTrials":279,"cells":1097},{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1112},{"trials":1099,"activeCount":73},[],{"trials":1101,"activeCount":73},[],{"trials":1103,"activeCount":73},[],{"trials":1105,"activeCount":73},[],{"trials":1107,"activeCount":73},[1108],{"nctId":1085,"briefTitle":1086,"status":79,"phases":1109,"primaryCompletion":688,"completion":688,"start":1088,"enrollment":152,"conditions":1110,"interventions":1111},[65],[1090],[1072,1092,1093],{"trials":1113,"activeCount":73},[],{"intervention":1093,"totalTrials":279,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1130},{"trials":1117,"activeCount":73},[],{"trials":1119,"activeCount":73},[],{"trials":1121,"activeCount":73},[],{"trials":1123,"activeCount":73},[],{"trials":1125,"activeCount":73},[1126],{"nctId":1085,"briefTitle":1086,"status":79,"phases":1127,"primaryCompletion":688,"completion":688,"start":1088,"enrollment":152,"conditions":1128,"interventions":1129},[65],[1090],[1072,1092,1093],{"trials":1131,"activeCount":73},[],{"intervention":493,"totalTrials":279,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1148},{"trials":1135,"activeCount":73},[],{"trials":1137,"activeCount":73},[],{"trials":1139,"activeCount":73},[],{"trials":1141,"activeCount":73},[],{"trials":1143,"activeCount":73},[1144],{"nctId":484,"briefTitle":485,"status":79,"phases":1145,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":1146,"interventions":1147},[65],[15],[492,493,494,495],{"trials":1149,"activeCount":73},[],{"intervention":494,"totalTrials":279,"cells":1151},{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1160,"NA":1166},{"trials":1153,"activeCount":73},[],{"trials":1155,"activeCount":73},[],{"trials":1157,"activeCount":73},[],{"trials":1159,"activeCount":73},[],{"trials":1161,"activeCount":73},[1162],{"nctId":484,"briefTitle":485,"status":79,"phases":1163,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":1164,"interventions":1165},[65],[15],[492,493,494,495],{"trials":1167,"activeCount":73},[],{"intervention":495,"totalTrials":279,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1178,"NA":1184},{"trials":1171,"activeCount":73},[],{"trials":1173,"activeCount":73},[],{"trials":1175,"activeCount":73},[],{"trials":1177,"activeCount":73},[],{"trials":1179,"activeCount":73},[1180],{"nctId":484,"briefTitle":485,"status":79,"phases":1181,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":1182,"interventions":1183},[65],[15],[492,493,494,495],{"trials":1185,"activeCount":73},[],{"intervention":1187,"totalTrials":279,"cells":1188},"Calcitriol",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1209},{"trials":1190,"activeCount":73},[],{"trials":1192,"activeCount":73},[],{"trials":1194,"activeCount":73},[],{"trials":1196,"activeCount":73},[],{"trials":1198,"activeCount":73},[1199],{"nctId":1200,"briefTitle":1201,"status":79,"phases":1202,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1208},"NCT02125279","Long Term Safety and Efficacy Study of Calcitriol 3 mcg\u002Fg Ointment in Pediatric Subjects With Plaque Psoriasis",[65],"2018-05","2014-05",54,[1207],"Psoriasis Vulgaris",[1187],{"trials":1210,"activeCount":73},[],{"intervention":550,"totalTrials":279,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1227},{"trials":1214,"activeCount":73},[],{"trials":1216,"activeCount":73},[],{"trials":1218,"activeCount":73},[],{"trials":1220,"activeCount":73},[],{"trials":1222,"activeCount":73},[1223],{"nctId":542,"briefTitle":543,"status":79,"phases":1224,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":1225,"interventions":1226},[65],[18],[519,550],{"trials":1228,"activeCount":73},[],{"intervention":1230,"totalTrials":279,"cells":1231},"Fluocinolone acetonide 0.1%\u002Fhydroquinone 4%\u002Ftretinoin 0.05% Cream in sequence with glycolic acid peels",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1251},{"trials":1233,"activeCount":73},[],{"trials":1235,"activeCount":73},[],{"trials":1237,"activeCount":73},[],{"trials":1239,"activeCount":73},[],{"trials":1241,"activeCount":73},[1242],{"nctId":1243,"briefTitle":1244,"status":79,"phases":1245,"primaryCompletion":1246,"completion":1246,"start":1247,"enrollment":145,"conditions":1248,"interventions":1250},"NCT00472966","Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma",[65],"2007-04","2006-11",[1249],"Melasma",[1230],{"trials":1252,"activeCount":73},[],{"intervention":1254,"totalTrials":279,"cells":1255},"Loceryl NL",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1275},{"trials":1257,"activeCount":73},[],{"trials":1259,"activeCount":73},[],{"trials":1261,"activeCount":73},[],{"trials":1263,"activeCount":73},[],{"trials":1265,"activeCount":73},[1266],{"nctId":1267,"briefTitle":1268,"status":79,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":145,"conditions":1272,"interventions":1273},"NCT02679911","Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer",[65],"2016-06","2015-09",[1090],[1254,1274],"Ciclopirox NL",{"trials":1276,"activeCount":73},[],{"intervention":1274,"totalTrials":279,"cells":1278},{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1293},{"trials":1280,"activeCount":73},[],{"trials":1282,"activeCount":73},[],{"trials":1284,"activeCount":73},[],{"trials":1286,"activeCount":73},[],{"trials":1288,"activeCount":73},[1289],{"nctId":1267,"briefTitle":1268,"status":79,"phases":1290,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":145,"conditions":1291,"interventions":1292},[65],[1090],[1254,1274],{"trials":1294,"activeCount":73},[],{"intervention":715,"totalTrials":279,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1311},{"trials":1298,"activeCount":73},[],{"trials":1300,"activeCount":73},[],{"trials":1302,"activeCount":73},[],{"trials":1304,"activeCount":73},[],{"trials":1306,"activeCount":73},[1307],{"nctId":708,"briefTitle":709,"status":79,"phases":1308,"primaryCompletion":437,"completion":437,"start":711,"enrollment":712,"conditions":1309,"interventions":1310},[65],[15],[695,715],{"trials":1312,"activeCount":73},[],{"intervention":759,"totalTrials":279,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1323,"NA":1329},{"trials":1316,"activeCount":73},[],{"trials":1318,"activeCount":73},[],{"trials":1320,"activeCount":73},[],{"trials":1322,"activeCount":73},[],{"trials":1324,"activeCount":73},[1325],{"nctId":753,"briefTitle":754,"status":79,"phases":1326,"primaryCompletion":624,"completion":624,"start":349,"enrollment":756,"conditions":1327,"interventions":1328},[65],[15],[729,759],{"trials":1330,"activeCount":73},[],{"intervention":1332,"totalTrials":279,"cells":1333},"Loceryl Nail Lacquer",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1353},{"trials":1335,"activeCount":73},[],{"trials":1337,"activeCount":73},[],{"trials":1339,"activeCount":73},[],{"trials":1341,"activeCount":73},[],{"trials":1343,"activeCount":73},[1344],{"nctId":1345,"briefTitle":1346,"status":79,"phases":1347,"primaryCompletion":555,"completion":555,"start":688,"enrollment":1348,"conditions":1349,"interventions":1350},"NCT02705664","Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%",[65],22,[1090],[1332,1351,1352],"Urea Ointment","Bifonazole Cream",{"trials":1354,"activeCount":73},[],{"intervention":1351,"totalTrials":279,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1371},{"trials":1358,"activeCount":73},[],{"trials":1360,"activeCount":73},[],{"trials":1362,"activeCount":73},[],{"trials":1364,"activeCount":73},[],{"trials":1366,"activeCount":73},[1367],{"nctId":1345,"briefTitle":1346,"status":79,"phases":1368,"primaryCompletion":555,"completion":555,"start":688,"enrollment":1348,"conditions":1369,"interventions":1370},[65],[1090],[1332,1351,1352],{"trials":1372,"activeCount":73},[],{"intervention":1352,"totalTrials":279,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1389},{"trials":1376,"activeCount":73},[],{"trials":1378,"activeCount":73},[],{"trials":1380,"activeCount":73},[],{"trials":1382,"activeCount":73},[],{"trials":1384,"activeCount":73},[1385],{"nctId":1345,"briefTitle":1346,"status":79,"phases":1386,"primaryCompletion":555,"completion":555,"start":688,"enrollment":1348,"conditions":1387,"interventions":1388},[65],[1090],[1332,1351,1352],{"trials":1390,"activeCount":73},[],{"intervention":1392,"totalTrials":279,"cells":1393},"Clobex Spray",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1411},{"trials":1395,"activeCount":73},[],{"trials":1397,"activeCount":73},[],{"trials":1399,"activeCount":73},[],{"trials":1401,"activeCount":73},[],{"trials":1403,"activeCount":73},[1404],{"nctId":1405,"briefTitle":1406,"status":79,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":386,"enrollment":982,"conditions":1409,"interventions":1410},"NCT01893567","Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%",[65],"2013-10",[30],[1392],{"trials":1412,"activeCount":73},[],{"intervention":1414,"totalTrials":279,"cells":1415},"Oracea",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1424,"NA":1434},{"trials":1417,"activeCount":73},[],{"trials":1419,"activeCount":73},[],{"trials":1421,"activeCount":73},[],{"trials":1423,"activeCount":73},[],{"trials":1425,"activeCount":73},[1426],{"nctId":1427,"briefTitle":1428,"status":79,"phases":1429,"primaryCompletion":955,"completion":955,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT01872715","Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea",[65],"2013-03",24,[399],[1414],{"trials":1435,"activeCount":73},[],{"intervention":1437,"totalTrials":279,"cells":1438},"Calcitriol 3 mcg\u002Fg ointment",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1456},{"trials":1440,"activeCount":73},[],{"trials":1442,"activeCount":73},[],{"trials":1444,"activeCount":73},[],{"trials":1446,"activeCount":73},[],{"trials":1448,"activeCount":73},[1449],{"nctId":1450,"briefTitle":1451,"status":79,"phases":1452,"primaryCompletion":687,"completion":687,"start":1430,"enrollment":1453,"conditions":1454,"interventions":1455},"NCT01766440","PK and PD Study of Calcitriol 3 mcg\u002Fg Ointment in Pediatric Subjects With Plaque Psoriasis",[65],18,[30],[1437],{"trials":1457,"activeCount":73},[],{"intervention":1459,"totalTrials":279,"cells":1460},"tetracaine 7% \u002F lidocaine 7% cream",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1481},{"trials":1462,"activeCount":73},[],{"trials":1464,"activeCount":73},[],{"trials":1466,"activeCount":73},[],{"trials":1468,"activeCount":73},[],{"trials":1470,"activeCount":73},[1471],{"nctId":1472,"briefTitle":1473,"status":270,"phases":1474,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":626,"conditions":1477,"interventions":1479},"NCT00716443","Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections",[65],"2008-09","2008-07",[1478],"Nasolabial Folds",[1459,1480],"benzocaine 20% \u002F lidocaine 6% \u002F tetracaine 4% ointment",{"trials":1482,"activeCount":73},[],{"intervention":1480,"totalTrials":279,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1499},{"trials":1486,"activeCount":73},[],{"trials":1488,"activeCount":73},[],{"trials":1490,"activeCount":73},[],{"trials":1492,"activeCount":73},[],{"trials":1494,"activeCount":73},[1495],{"nctId":1472,"briefTitle":1473,"status":270,"phases":1496,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":626,"conditions":1497,"interventions":1498},[65],[1478],[1459,1480],{"trials":1500,"activeCount":73},[],{"intervention":1502,"totalTrials":279,"cells":1503},"Metronidazole gel 1%",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1512,"NA":1522},{"trials":1505,"activeCount":73},[],{"trials":1507,"activeCount":73},[],{"trials":1509,"activeCount":73},[],{"trials":1511,"activeCount":73},[],{"trials":1513,"activeCount":73},[1514],{"nctId":1515,"briefTitle":1516,"status":79,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1521},"NCT00436527","Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application",[65],"2006-08",26,[18],[1502],{"trials":1523,"activeCount":73},[],{"intervention":1525,"totalTrials":279,"cells":1526},"Adapalene 0.3% \u002F benzoyl peroxide 2.5% emulsion gel",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1535,"NA":1548},{"trials":1528,"activeCount":73},[],{"trials":1530,"activeCount":73},[],{"trials":1532,"activeCount":73},[],{"trials":1534,"activeCount":73},[],{"trials":1536,"activeCount":73},[1537],{"nctId":1538,"briefTitle":1539,"status":79,"phases":1540,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT02899000","A Treatment for Severe Inflammatory Acne Subjects",[65],"2017-03-28","2017-06-27","2016-07-29",186,[15],[1525,1547],"Oral doxycycline hyclate",{"trials":1549,"activeCount":73},[],{"intervention":1547,"totalTrials":279,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1558,"PHASE4":1560,"NA":1566},{"trials":1553,"activeCount":73},[],{"trials":1555,"activeCount":73},[],{"trials":1557,"activeCount":73},[],{"trials":1559,"activeCount":73},[],{"trials":1561,"activeCount":73},[1562],{"nctId":1538,"briefTitle":1539,"status":79,"phases":1563,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1564,"interventions":1565},[65],[15],[1525,1547],{"trials":1567,"activeCount":73},[],{"intervention":664,"totalTrials":279,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1584},{"trials":1571,"activeCount":73},[],{"trials":1573,"activeCount":73},[],{"trials":1575,"activeCount":73},[],{"trials":1577,"activeCount":73},[],{"trials":1579,"activeCount":73},[1580],{"nctId":655,"briefTitle":656,"status":79,"phases":1581,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":1582,"interventions":1583},[65],[662],[632,664],{"trials":1585,"activeCount":73},[],{"intervention":1587,"totalTrials":279,"cells":1588},"adapalen 0.1%",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1608},{"trials":1590,"activeCount":73},[],{"trials":1592,"activeCount":73},[],{"trials":1594,"activeCount":73},[],{"trials":1596,"activeCount":73},[],{"trials":1598,"activeCount":73},[1599],{"nctId":1600,"briefTitle":1601,"status":79,"phases":1602,"primaryCompletion":659,"completion":1603,"start":1604,"enrollment":745,"conditions":1605,"interventions":1607},"NCT00971282","Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins",[65],"2009-05","2008-12",[1606],"Healthy Skin",[1587],{"trials":1609,"activeCount":73},[],{"intervention":1611,"totalTrials":279,"cells":1612},"Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1621,"NA":1631},{"trials":1614,"activeCount":73},[],{"trials":1616,"activeCount":73},[],{"trials":1618,"activeCount":73},[],{"trials":1620,"activeCount":73},[],{"trials":1622,"activeCount":73},[1623],{"nctId":1624,"briefTitle":1625,"status":79,"phases":1626,"primaryCompletion":1246,"completion":1246,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1630},"NCT00469183","Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma",[65],"2006-05",70,[1249],[1611],{"trials":1632,"activeCount":73},[],{"intervention":1634,"totalTrials":279,"cells":1635},"Adapalene\u002FBPO Gel",{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1642,"PHASE4":1644,"NA":1652},{"trials":1637,"activeCount":73},[],{"trials":1639,"activeCount":73},[],{"trials":1641,"activeCount":73},[],{"trials":1643,"activeCount":73},[],{"trials":1645,"activeCount":73},[1646],{"nctId":1647,"briefTitle":1648,"status":79,"phases":1649,"primaryCompletion":577,"completion":577,"start":1408,"enrollment":660,"conditions":1650,"interventions":1651},"NCT01951417","Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris",[65],[21],[1634],{"trials":1653,"activeCount":73},[],{"intervention":1655,"totalTrials":279,"cells":1656},"Azzalure or Dysport",{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1676},{"trials":1658,"activeCount":73},[],{"trials":1660,"activeCount":73},[],{"trials":1662,"activeCount":73},[],{"trials":1664,"activeCount":73},[],{"trials":1666,"activeCount":73},[1667],{"nctId":1668,"briefTitle":1669,"status":79,"phases":1670,"primaryCompletion":1671,"completion":1671,"start":809,"enrollment":1672,"conditions":1673,"interventions":1675},"NCT02297516","Safety and Efficacy of Azzalure\u002FDysport, Restylane\u002FEmervel Filler and Restylane Skinbooster Treatment",[65],"2017-03",65,[1674],"Aesthetics",[1655],{"trials":1677,"activeCount":73},[],{"intervention":1679,"totalTrials":279,"cells":1680},"Product A",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1701},{"trials":1682,"activeCount":73},[],{"trials":1684,"activeCount":73},[],{"trials":1686,"activeCount":73},[],{"trials":1688,"activeCount":73},[],{"trials":1690,"activeCount":73},[1691],{"nctId":1692,"briefTitle":1693,"status":79,"phases":1694,"primaryCompletion":1695,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1699},"NCT02755545","A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments",[65],"2017-04-04","2016-05-01",127,[21],[1679,1700],"Product B",{"trials":1702,"activeCount":73},[],{"intervention":1700,"totalTrials":279,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1713,"NA":1719},{"trials":1706,"activeCount":73},[],{"trials":1708,"activeCount":73},[],{"trials":1710,"activeCount":73},[],{"trials":1712,"activeCount":73},[],{"trials":1714,"activeCount":73},[1715],{"nctId":1692,"briefTitle":1693,"status":79,"phases":1716,"primaryCompletion":1695,"completion":1695,"start":1696,"enrollment":1697,"conditions":1717,"interventions":1718},[65],[21],[1679,1700],{"trials":1720,"activeCount":73},[],{"intervention":1722,"totalTrials":279,"cells":1723},"Cetaphil Healing Ointment",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1745},{"trials":1725,"activeCount":73},[],{"trials":1727,"activeCount":73},[],{"trials":1729,"activeCount":73},[],{"trials":1731,"activeCount":73},[],{"trials":1733,"activeCount":73},[1734],{"nctId":1735,"briefTitle":1736,"status":79,"phases":1737,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1744},"NCT05686928","Healing Ointment Usage Post-surgical Procedure",[65],"2022-10-31","2022-11-30","2022-08-17",15,[1743],"Surgical Wound",[1722],{"trials":1746,"activeCount":73},[],{"intervention":725,"totalTrials":279,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1757,"NA":1763},{"trials":1750,"activeCount":73},[],{"trials":1752,"activeCount":73},[],{"trials":1754,"activeCount":73},[],{"trials":1756,"activeCount":73},[],{"trials":1758,"activeCount":73},[1759],{"nctId":717,"briefTitle":718,"status":79,"phases":1760,"primaryCompletion":720,"completion":720,"start":534,"enrollment":721,"conditions":1761,"interventions":1762},[65],[15],[724,725],{"trials":1764,"activeCount":73},[],{"intervention":1766,"totalTrials":279,"cells":1767},"Methyl Aminolaevulinate 16% Cream",{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1774,"PHASE4":1776,"NA":1787},{"trials":1769,"activeCount":73},[],{"trials":1771,"activeCount":73},[],{"trials":1773,"activeCount":73},[],{"trials":1775,"activeCount":73},[],{"trials":1777,"activeCount":73},[1778],{"nctId":1779,"briefTitle":1780,"status":79,"phases":1781,"primaryCompletion":1782,"completion":1782,"start":1783,"enrollment":152,"conditions":1784,"interventions":1786},"NCT03511326","PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK",[65],"2017-11-28","2017-06-07",[1785],"Actinic Keratoses",[1766],{"trials":1788,"activeCount":73},[],{"intervention":1790,"totalTrials":279,"cells":1791},"Calcipotriene and betamethasone dipropionate ointment",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1811},{"trials":1793,"activeCount":73},[],{"trials":1795,"activeCount":73},[],{"trials":1797,"activeCount":73},[],{"trials":1799,"activeCount":73},[],{"trials":1801,"activeCount":73},[1802],{"nctId":1803,"briefTitle":1804,"status":79,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1518,"enrollment":1807,"conditions":1808,"interventions":1809},"NCT00437255","Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis",[65],"2007-06",122,[30],[1810,1790],"Clobetasol Propionate, 0.05%",{"trials":1812,"activeCount":73},[],{"intervention":1814,"totalTrials":279,"cells":1815},"Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1836},{"trials":1817,"activeCount":73},[],{"trials":1819,"activeCount":73},[],{"trials":1821,"activeCount":73},[],{"trials":1823,"activeCount":73},[],{"trials":1825,"activeCount":73},[1826],{"nctId":1827,"briefTitle":1828,"status":270,"phases":1829,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1834},"NCT00669071","Treatment w\u002F Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma",[65],"2008-10","2008-01",56,[1249],[1814,1835],"Cetaphil® Moisturizing Cream as Inactive Control",{"trials":1837,"activeCount":73},[],{"intervention":1835,"totalTrials":279,"cells":1839},{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1846,"PHASE4":1848,"NA":1854},{"trials":1841,"activeCount":73},[],{"trials":1843,"activeCount":73},[],{"trials":1845,"activeCount":73},[],{"trials":1847,"activeCount":73},[],{"trials":1849,"activeCount":73},[1850],{"nctId":1827,"briefTitle":1828,"status":270,"phases":1851,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1832,"conditions":1852,"interventions":1853},[65],[1249],[1814,1835],{"trials":1855,"activeCount":73},[],{"intervention":1857,"totalTrials":279,"cells":1858},"Adapalene 0.1%\u002FBenzoyl Peroxide 2.5% Gel",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1865,"PHASE4":1867,"NA":1877},{"trials":1860,"activeCount":73},[],{"trials":1862,"activeCount":73},[],{"trials":1864,"activeCount":73},[],{"trials":1866,"activeCount":73},[],{"trials":1868,"activeCount":73},[1869],{"nctId":1870,"briefTitle":1871,"status":79,"phases":1872,"primaryCompletion":448,"completion":448,"start":1873,"enrollment":745,"conditions":1874,"interventions":1876},"NCT00907101","Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes",[65],"2009-06",[1875],"P Acnes Colonization",[1857],{"trials":1878,"activeCount":73},[],{"intervention":560,"totalTrials":279,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1895},{"trials":1882,"activeCount":73},[],{"trials":1884,"activeCount":73},[],{"trials":1886,"activeCount":73},[],{"trials":1888,"activeCount":73},[],{"trials":1890,"activeCount":73},[1891],{"nctId":552,"briefTitle":553,"status":79,"phases":1892,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":1893,"interventions":1894},[65],[18],[560,519],{"trials":1896,"activeCount":73},[],{"intervention":1898,"totalTrials":279,"cells":1899},"Clobetasol Propionate 0.05% Spray",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1920},{"trials":1901,"activeCount":73},[],{"trials":1903,"activeCount":73},[],{"trials":1905,"activeCount":73},[],{"trials":1907,"activeCount":73},[],{"trials":1909,"activeCount":73},[1910],{"nctId":1911,"briefTitle":1912,"status":79,"phases":1913,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1918},"NCT00436540","A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam",[65],"2007-01","2006-03",78,[35],[1898,1919],"Clobetasol Propionate 0.05% Foam",{"trials":1921,"activeCount":73},[],{"intervention":1919,"totalTrials":279,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1938},{"trials":1925,"activeCount":73},[],{"trials":1927,"activeCount":73},[],{"trials":1929,"activeCount":73},[],{"trials":1931,"activeCount":73},[],{"trials":1933,"activeCount":73},[1934],{"nctId":1911,"briefTitle":1912,"status":79,"phases":1935,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1916,"conditions":1936,"interventions":1937},[65],[35],[1898,1919],{"trials":1939,"activeCount":73},[],{"intervention":1941,"totalTrials":279,"cells":1942},"Brimonidine",{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1949,"PHASE4":1951,"NA":1961},{"trials":1944,"activeCount":73},[],{"trials":1946,"activeCount":73},[],{"trials":1948,"activeCount":73},[],{"trials":1950,"activeCount":73},[],{"trials":1952,"activeCount":73},[1953],{"nctId":1954,"briefTitle":1955,"status":79,"phases":1956,"primaryCompletion":924,"completion":924,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1960},"NCT02249065","Mirvaso in Use Study",[65],"2014-09",205,[18],[1941],{"trials":1962,"activeCount":73},[],{"intervention":1964,"totalTrials":279,"cells":1965},"clobetasol propionate spray",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1985},{"trials":1967,"activeCount":73},[],{"trials":1969,"activeCount":73},[],{"trials":1971,"activeCount":73},[],{"trials":1973,"activeCount":73},[],{"trials":1975,"activeCount":73},[1976],{"nctId":1977,"briefTitle":1978,"status":79,"phases":1979,"primaryCompletion":744,"completion":744,"start":1980,"enrollment":1981,"conditions":1982,"interventions":1983},"NCT00733954","Efficacy\u002FSafety\u002FSubject Satisfaction\u002FDuration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis",[65],"2007-08",250,[30],[1964,1984],"clobetasol propionate ointment",{"trials":1986,"activeCount":73},[],{"intervention":1984,"totalTrials":279,"cells":1988},{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":2003},{"trials":1990,"activeCount":73},[],{"trials":1992,"activeCount":73},[],{"trials":1994,"activeCount":73},[],{"trials":1996,"activeCount":73},[],{"trials":1998,"activeCount":73},[1999],{"nctId":1977,"briefTitle":1978,"status":79,"phases":2000,"primaryCompletion":744,"completion":744,"start":1980,"enrollment":1981,"conditions":2001,"interventions":2002},[65],[30],[1964,1984],{"trials":2004,"activeCount":73},[],{"intervention":2006,"totalTrials":279,"cells":2007},"Adapalene 0.1% and Benzoyl Peroxide 2.5% gel",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2025},{"trials":2009,"activeCount":73},[],{"trials":2011,"activeCount":73},[],{"trials":2013,"activeCount":73},[],{"trials":2015,"activeCount":73},[],{"trials":2017,"activeCount":73},[2018],{"nctId":2019,"briefTitle":2020,"status":79,"phases":2021,"primaryCompletion":436,"completion":436,"start":2022,"enrollment":745,"conditions":2023,"interventions":2024},"NCT01209949","Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris",[65],"2010-10",[15],[2006],{"trials":2026,"activeCount":73},[],{"intervention":787,"totalTrials":279,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2035,"PHASE4":2037,"NA":2043},{"trials":2030,"activeCount":73},[],{"trials":2032,"activeCount":73},[],{"trials":2034,"activeCount":73},[],{"trials":2036,"activeCount":73},[],{"trials":2038,"activeCount":73},[2039],{"nctId":779,"briefTitle":780,"status":79,"phases":2040,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":2041,"interventions":2042},[65],[15],[341,787,788],{"trials":2044,"activeCount":73},[],{"intervention":788,"totalTrials":279,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2061},{"trials":2048,"activeCount":73},[],{"trials":2050,"activeCount":73},[],{"trials":2052,"activeCount":73},[],{"trials":2054,"activeCount":73},[],{"trials":2056,"activeCount":73},[2057],{"nctId":779,"briefTitle":780,"status":79,"phases":2058,"primaryCompletion":782,"completion":782,"start":783,"enrollment":784,"conditions":2059,"interventions":2060},[65],[15],[341,787,788],{"trials":2062,"activeCount":73},[],{"intervention":960,"totalTrials":279,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2071,"PHASE4":2073,"NA":2079},{"trials":2066,"activeCount":73},[],{"trials":2068,"activeCount":73},[],{"trials":2070,"activeCount":73},[],{"trials":2072,"activeCount":73},[],{"trials":2074,"activeCount":73},[2075],{"nctId":952,"briefTitle":953,"status":79,"phases":2076,"primaryCompletion":955,"completion":955,"start":956,"enrollment":957,"conditions":2077,"interventions":2078},[65],[18],[930,960],{"trials":2080,"activeCount":73},[],{"intervention":2082,"totalTrials":279,"cells":2083},"Alluzience",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2088,"PHASE3":2090,"PHASE4":2092,"NA":2104},{"trials":2085,"activeCount":73},[],{"trials":2087,"activeCount":73},[],{"trials":2089,"activeCount":73},[],{"trials":2091,"activeCount":73},[],{"trials":2093,"activeCount":73},[2094],{"nctId":2095,"briefTitle":2096,"status":79,"phases":2097,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":2101,"interventions":2102},"NCT05277337","Study Comparing Treatment With Alluzience vs Reconstituted Toxin",[65],"2022-10-12","2022-02-04",150,[24],[2082,2103],"powder BoNT-A",{"trials":2105,"activeCount":73},[],{"intervention":2103,"totalTrials":279,"cells":2107},{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2114,"PHASE4":2116,"NA":2122},{"trials":2109,"activeCount":73},[],{"trials":2111,"activeCount":73},[],{"trials":2113,"activeCount":73},[],{"trials":2115,"activeCount":73},[],{"trials":2117,"activeCount":73},[2118],{"nctId":2095,"briefTitle":2096,"status":79,"phases":2119,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":2120,"interventions":2121},[65],[24],[2082,2103],{"trials":2123,"activeCount":73},[],{"intervention":2125,"totalTrials":279,"cells":2126},"\"Cetaphil Healing Ointment\"",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2146},{"trials":2128,"activeCount":73},[],{"trials":2130,"activeCount":73},[],{"trials":2132,"activeCount":73},[],{"trials":2134,"activeCount":73},[],{"trials":2136,"activeCount":73},[2137],{"nctId":2138,"briefTitle":2139,"status":79,"phases":2140,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":1519,"conditions":2143,"interventions":2145},"NCT06015217","A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash",[65],"2023-12-13","2023-08-25",[2144],"Diaper Rash",[2125],{"trials":2147,"activeCount":73},[],{"intervention":2149,"totalTrials":279,"cells":2150},"doxycycline (Oracea®) 40 mg modified release as monotherapy",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2169},{"trials":2152,"activeCount":73},[],{"trials":2154,"activeCount":73},[],{"trials":2156,"activeCount":73},[],{"trials":2158,"activeCount":73},[],{"trials":2160,"activeCount":73},[2161],{"nctId":2162,"briefTitle":2163,"status":79,"phases":2164,"primaryCompletion":1028,"completion":1028,"start":659,"enrollment":2165,"conditions":2166,"interventions":2167},"NCT00892281","ORCA - Oracea® for Rosacea: A Community-based Assessment",[65],1421,[18],[2149,2168],"doxycycline (Oracea®) 40 mg modified release as add-on therapy",{"trials":2170,"activeCount":73},[],{"intervention":2168,"totalTrials":279,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2181,"NA":2187},{"trials":2174,"activeCount":73},[],{"trials":2176,"activeCount":73},[],{"trials":2178,"activeCount":73},[],{"trials":2180,"activeCount":73},[],{"trials":2182,"activeCount":73},[2183],{"nctId":2162,"briefTitle":2163,"status":79,"phases":2184,"primaryCompletion":1028,"completion":1028,"start":659,"enrollment":2165,"conditions":2185,"interventions":2186},[65],[18],[2149,2168],{"trials":2188,"activeCount":73},[],{"intervention":2190,"totalTrials":279,"cells":2191},"Lidocaine 7% + Tetracaine 7% cream",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2198,"PHASE4":2200,"NA":2208},{"trials":2193,"activeCount":73},[],{"trials":2195,"activeCount":73},[],{"trials":2197,"activeCount":73},[],{"trials":2199,"activeCount":73},[],{"trials":2201,"activeCount":73},[2202],{"nctId":2203,"briefTitle":2204,"status":79,"phases":2205,"primaryCompletion":720,"completion":720,"start":720,"enrollment":745,"conditions":2206,"interventions":2207},"NCT01545765","Anesthetic Effect Duration Assessment",[65],[86],[2190],{"trials":2209,"activeCount":73},[],{"intervention":2211,"totalTrials":279,"cells":2212},"Facial Moisturizer with SPF 50+",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2221,"NA":2231},{"trials":2214,"activeCount":73},[],{"trials":2216,"activeCount":73},[],{"trials":2218,"activeCount":73},[],{"trials":2220,"activeCount":73},[],{"trials":2222,"activeCount":73},[2223],{"nctId":2224,"briefTitle":2225,"status":79,"phases":2226,"primaryCompletion":625,"completion":624,"start":647,"enrollment":2227,"conditions":2228,"interventions":2230},"NCT01892657","Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test",[65],128,[2229],"Skin Irritation",[2211],{"trials":2232,"activeCount":73},[],{"intervention":2234,"totalTrials":313,"cells":2235},"Adapalene lotion 0.1%",{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2258,"PHASE3":2260,"PHASE4":2277,"NA":2279},{"trials":2237,"activeCount":73},[],{"trials":2239,"activeCount":73},[2240,2250],{"nctId":2241,"briefTitle":2242,"status":79,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":743,"enrollment":2245,"conditions":2246,"interventions":2247},"NCT01046565","Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin",[62],"2010-02",75,[409],[2248,2249],"adapalene cream 0.1%","adapalene lotion 0.1%",{"nctId":2251,"briefTitle":2252,"status":79,"phases":2253,"primaryCompletion":2244,"completion":2244,"start":743,"enrollment":2254,"conditions":2255,"interventions":2256},"NCT01046396","Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin",[62],69,[409],[2257,2249],"adapalene cream 0.1% and adapalene lotion 0.1%",{"trials":2259,"activeCount":73},[],{"trials":2261,"activeCount":73},[2262,2271],{"nctId":2263,"briefTitle":2264,"status":79,"phases":2265,"primaryCompletion":449,"completion":1604,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2269},"NCT00599521","Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",[64],"2007-11",1067,[15],[2234,2270],"Adapalene Lotion Vehicle",{"nctId":2272,"briefTitle":2264,"status":79,"phases":2273,"primaryCompletion":1830,"completion":449,"start":2266,"enrollment":2274,"conditions":2275,"interventions":2276},"NCT00598832",[64],1075,[15],[2234,2270],{"trials":2278,"activeCount":73},[],{"trials":2280,"activeCount":73},[],{"intervention":2282,"totalTrials":11,"cells":2283},"botulinum toxin",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2296,"PHASE3":2298,"PHASE4":2320,"NA":2322},{"trials":2285,"activeCount":73},[],{"trials":2287,"activeCount":73},[2288],{"nctId":2289,"briefTitle":2290,"status":79,"phases":2291,"primaryCompletion":689,"completion":689,"start":577,"enrollment":1348,"conditions":2292,"interventions":2294},"NCT02139319","Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee",[62],[2293],"Knee Osteoarthritis",[2295],"Botulinum toxin",{"trials":2297,"activeCount":73},[],{"trials":2299,"activeCount":73},[2300,2310],{"nctId":2301,"briefTitle":2302,"status":79,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2309},"NCT04249583","Treatment of Moderate to Severe Glabellar Lines",[64],"2020-08-07","2021-01-05","2020-02-10",300,[24],[2282],{"nctId":2311,"briefTitle":2312,"status":79,"phases":2313,"primaryCompletion":2314,"completion":2315,"start":2306,"enrollment":2316,"conditions":2317,"interventions":2319},"NCT04249687","Treatment of Moderate to Severe Lateral Canthal Lines",[64],"2020-09-25","2021-02-10",303,[2318],"Lateral Canthal Lines",[2282],{"trials":2321,"activeCount":73},[],{"trials":2323,"activeCount":73},[],{"intervention":2325,"totalTrials":11,"cells":2326},"Botulinum Toxin Type A",{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2341,"PHASE4":2361,"NA":2363},{"trials":2328,"activeCount":73},[],{"trials":2330,"activeCount":73},[],{"trials":2332,"activeCount":73},[2333],{"nctId":2334,"briefTitle":2335,"status":79,"phases":2336,"primaryCompletion":809,"completion":2337,"start":1957,"enrollment":2338,"conditions":2339,"interventions":2340},"NCT02236312","Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines",[63],"2015-05",359,[24],[2325],{"trials":2342,"activeCount":73},[2343,2353],{"nctId":2344,"briefTitle":2345,"status":79,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":2349,"conditions":2350,"interventions":2352},"NCT01529203","Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range",[64],"2013-04","2012-02",60,[2351],"Aging",[2325],{"nctId":2354,"briefTitle":2355,"status":79,"phases":2356,"primaryCompletion":720,"completion":720,"start":436,"enrollment":2357,"conditions":2358,"interventions":2360},"NCT01308060","A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)",[64],335,[2359],"Canthal Lines",[2325],{"trials":2362,"activeCount":73},[],{"trials":2364,"activeCount":73},[],{"intervention":441,"totalTrials":11,"cells":2366},{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2377,"PHASE4":2396,"NA":2398},{"trials":2368,"activeCount":73},[],{"trials":2370,"activeCount":73},[],{"trials":2372,"activeCount":73},[2373],{"nctId":432,"briefTitle":433,"status":79,"phases":2374,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":2375,"interventions":2376},[63],[18],[441,423,441,441,423],{"trials":2378,"activeCount":73},[2379,2389],{"nctId":2380,"briefTitle":2381,"status":79,"phases":2382,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":2386,"conditions":2387,"interventions":2388},"NCT01355471","Phase 3 Efficacy and Safety Study of CD07805\u002F47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea",[64],"2011-11","2012-01","2011-05",293,[18],[441],{"nctId":2390,"briefTitle":2381,"status":79,"phases":2391,"primaryCompletion":956,"completion":388,"start":2385,"enrollment":2392,"conditions":2393,"interventions":2394},"NCT01355458",[64],260,[18],[2395],"CD07805\u002F47 gel",{"trials":2397,"activeCount":73},[],{"trials":2399,"activeCount":73},[],{"intervention":2401,"totalTrials":11,"cells":2402},"QM1114-DP",{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2409,"PHASE4":2443,"NA":2445},{"trials":2404,"activeCount":73},[],{"trials":2406,"activeCount":73},[],{"trials":2408,"activeCount":73},[],{"trials":2410,"activeCount":73},[2411,2423,2433],{"nctId":2412,"briefTitle":2413,"status":79,"phases":2414,"primaryCompletion":2415,"completion":2416,"start":2417,"enrollment":2418,"conditions":2419,"interventions":2421},"NCT05463965","A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines",[64],"2023-01-29","2023-06-15","2022-07-29",605,[2420],"Moderate to Severe Glabellar Lines",[2401,2422],"OnabotulinumtoxinA",{"nctId":2424,"briefTitle":2425,"status":79,"phases":2426,"primaryCompletion":2427,"completion":2428,"start":2429,"enrollment":2430,"conditions":2431,"interventions":2432},"NCT05148000","Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines",[64],"2023-03-31","2023-06-23","2023-01-23",25,[24,2359],[2401],{"nctId":2434,"briefTitle":2435,"status":79,"phases":2436,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":2441,"interventions":2442},"NCT05146999","Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines",[64],"2022-10-28","2023-09-01","2022-05-09",132,[24],[2401],{"trials":2444,"activeCount":73},[],{"trials":2446,"activeCount":73},[],{"intervention":2270,"totalTrials":156,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2465,"NA":2467},{"trials":2450,"activeCount":73},[],{"trials":2452,"activeCount":73},[],{"trials":2454,"activeCount":73},[],{"trials":2456,"activeCount":73},[2457,2461],{"nctId":2263,"briefTitle":2264,"status":79,"phases":2458,"primaryCompletion":449,"completion":1604,"start":2266,"enrollment":2267,"conditions":2459,"interventions":2460},[64],[15],[2234,2270],{"nctId":2272,"briefTitle":2264,"status":79,"phases":2462,"primaryCompletion":1830,"completion":449,"start":2266,"enrollment":2274,"conditions":2463,"interventions":2464},[64],[15],[2234,2270],{"trials":2466,"activeCount":73},[],{"trials":2468,"activeCount":73},[],{"intervention":2470,"totalTrials":156,"cells":2471},"Metvix® cream",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2501,"NA":2503},{"trials":2473,"activeCount":73},[],{"trials":2475,"activeCount":73},[],{"trials":2477,"activeCount":73},[],{"trials":2479,"activeCount":73},[2480,2491],{"nctId":2481,"briefTitle":2482,"status":79,"phases":2483,"primaryCompletion":2484,"completion":2485,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2490},"NCT00469417","Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma",[64],"2001-09-05","2005-04","1999-10-18",120,[2489],"Superficial Basal Cell Carcinoma",[2470],{"nctId":2492,"briefTitle":2493,"status":79,"phases":2494,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":2498,"interventions":2500},"NCT00473343","Metvix PDT in Participant With \"High Risk\" Basal Cell Carcinoma",[64],"2006-06","2000-09",102,[2499],"Basal Cell Carcinoma",[2470],{"trials":2502,"activeCount":73},[],{"trials":2504,"activeCount":73},[],{"intervention":2506,"totalTrials":156,"cells":2507},"botulinum toxin neuromodulator",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2538,"NA":2540},{"trials":2509,"activeCount":73},[],{"trials":2511,"activeCount":73},[],{"trials":2513,"activeCount":73},[],{"trials":2515,"activeCount":73},[2516,2527],{"nctId":2517,"briefTitle":2518,"status":79,"phases":2519,"primaryCompletion":2520,"completion":2521,"start":2522,"enrollment":2523,"conditions":2524,"interventions":2526},"NCT04225260","Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines",[64],"2021-04-12","2021-05-21","2020-01-27",902,[2525,2318],"Glabellar Lines",[2506],{"nctId":2528,"briefTitle":2529,"status":79,"phases":2530,"primaryCompletion":2531,"completion":2532,"start":2306,"enrollment":2533,"conditions":2534,"interventions":2537},"NCT04247074","Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination",[64],"2020-10-02","2021-02-26",413,[2535,2536],"Glabellar Frown Lines (GL)","Lateral Canthal Lines (LCL)",[2506],{"trials":2539,"activeCount":73},[],{"trials":2541,"activeCount":73},[],{"intervention":224,"totalTrials":156,"cells":2543},{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2559,"PHASE4":2565,"NA":2567},{"trials":2545,"activeCount":73},[],{"trials":2547,"activeCount":73},[],{"trials":2549,"activeCount":73},[2550],{"nctId":2551,"briefTitle":2552,"status":79,"phases":2553,"primaryCompletion":2554,"completion":2554,"start":2555,"enrollment":1628,"conditions":2556,"interventions":2557},"NCT03181503","Safety and Efficacy of Nemolizumab in PN",[63],"2018-09-26","2017-10-02",[32],[2558,224],"CD14152 Dose A",{"trials":2560,"activeCount":73},[2561],{"nctId":215,"briefTitle":216,"status":217,"phases":2562,"primaryCompletion":219,"completion":219,"start":220,"enrollment":73,"conditions":2563,"interventions":2564},[64],[222],[41,224],{"trials":2566,"activeCount":73},[],{"trials":2568,"activeCount":73},[],{"intervention":2570,"totalTrials":156,"cells":2571},"CD07805\u002F47 gel 0.5%",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2576,"PHASE3":2578,"PHASE4":2598,"NA":2600},{"trials":2573,"activeCount":73},[],{"trials":2575,"activeCount":73},[],{"trials":2577,"activeCount":73},[],{"trials":2579,"activeCount":73},[2580,2589],{"nctId":2581,"briefTitle":2582,"status":79,"phases":2583,"primaryCompletion":2584,"completion":2585,"start":608,"enrollment":2586,"conditions":2587,"interventions":2588},"NCT01318733","Study of CD07805\u002F47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea",[64],"2012-06","2012-07",449,[18],[2570],{"nctId":2590,"briefTitle":2591,"status":217,"phases":2592,"primaryCompletion":1271,"enrollment":73,"conditions":2593,"interventions":2595},"NCT01882712","Phase 3 Efficacy and Safety Study of CD07805\u002F47 Topical Gel in Subjects With Persistent Facial Erythema",[64],[2594],"Erythema",[2596,2597],"CD07805\u002F47 Gel 0.5%","CD07805\u002F47 Gel Placebo",{"trials":2599,"activeCount":73},[],{"trials":2601,"activeCount":73},[],{"intervention":393,"totalTrials":156,"cells":2603},{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2620,"NA":2622},{"trials":2605,"activeCount":73},[],{"trials":2607,"activeCount":73},[],{"trials":2609,"activeCount":73},[],{"trials":2611,"activeCount":73},[2612,2616],{"nctId":383,"briefTitle":384,"status":79,"phases":2613,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":2614,"interventions":2615},[64],[391],[393,372],{"nctId":395,"briefTitle":384,"status":79,"phases":2617,"primaryCompletion":387,"completion":387,"start":388,"enrollment":397,"conditions":2618,"interventions":2619},[64],[399],[393,372],{"trials":2621,"activeCount":73},[],{"trials":2623,"activeCount":73},[],{"intervention":2597,"totalTrials":156,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2648,"NA":2650},{"trials":2627,"activeCount":73},[],{"trials":2629,"activeCount":73},[],{"trials":2631,"activeCount":73},[],{"trials":2633,"activeCount":73},[2634,2638],{"nctId":2590,"briefTitle":2591,"status":217,"phases":2635,"primaryCompletion":1271,"enrollment":73,"conditions":2636,"interventions":2637},[64],[2594],[2596,2597],{"nctId":2639,"briefTitle":2640,"status":79,"phases":2641,"primaryCompletion":1408,"completion":1408,"start":2642,"enrollment":2643,"conditions":2644,"interventions":2645},"NCT01789775","Phase 3 Efficacy and Safety Study of CD07805\u002F47 Topical Gel in Subjects With Facial Erythema of Rosacea",[64],"2012-12",114,[18],[2646,2647],"Drug: CD07805\u002F47 gel","CD07805\u002F47 gel Placebo",{"trials":2649,"activeCount":73},[],{"trials":2651,"activeCount":73},[],{"intervention":2653,"totalTrials":156,"cells":2654},"GK530G",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2680,"NA":2682},{"trials":2656,"activeCount":73},[],{"trials":2658,"activeCount":73},[],{"trials":2660,"activeCount":73},[],{"trials":2662,"activeCount":73},[2663,2673],{"nctId":2664,"briefTitle":2665,"status":79,"phases":2666,"primaryCompletion":2667,"completion":2667,"start":577,"enrollment":2668,"conditions":2669,"interventions":2670},"NCT02073448","Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.",[64],"2014-10",417,[15],[2653,2671,2672],"CD0271","CD1579",{"nctId":2674,"briefTitle":2675,"status":79,"phases":2676,"primaryCompletion":981,"completion":981,"start":1004,"enrollment":2677,"conditions":2678,"interventions":2679},"NCT01910064","A Long Term Study of GK530G in Subjects With Acne Vulgaris",[64],436,[15],[2653],{"trials":2681,"activeCount":73},[],{"trials":2683,"activeCount":73},[],{"intervention":2685,"totalTrials":279,"cells":2686},"PDT with Metvix 160 mg\u002Fg cream",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2704,"NA":2706},{"trials":2688,"activeCount":73},[],{"trials":2690,"activeCount":73},[],{"trials":2692,"activeCount":73},[],{"trials":2694,"activeCount":73},[2695],{"nctId":2696,"briefTitle":2697,"status":79,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":2701,"conditions":2702,"interventions":2703},"NCT00472043","PDT With Metvix 160 mg\u002Fg Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma",[64],"2002-09-30","2000-10-01",66,[2499],[2685],{"trials":2705,"activeCount":73},[],{"trials":2707,"activeCount":73},[],{"intervention":2709,"totalTrials":279,"cells":2710},"Adapalene BPO Gel associated with Doxycyline Hyclate",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2729,"NA":2731},{"trials":2712,"activeCount":73},[],{"trials":2714,"activeCount":73},[],{"trials":2716,"activeCount":73},[],{"trials":2718,"activeCount":73},[2719],{"nctId":2720,"briefTitle":2721,"status":79,"phases":2722,"primaryCompletion":2723,"completion":2723,"start":624,"enrollment":2724,"conditions":2725,"interventions":2727},"NCT00688064","Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris",[64],"2009-02",459,[2726],"Severe Acne Vulgaris",[2709,2728],"Vehicle Gel associated with Doxycycline Hyclate",{"trials":2730,"activeCount":73},[],{"trials":2732,"activeCount":73},[],{"intervention":2728,"totalTrials":279,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":73},[],{"trials":2738,"activeCount":73},[],{"trials":2740,"activeCount":73},[],{"trials":2742,"activeCount":73},[2743],{"nctId":2720,"briefTitle":2721,"status":79,"phases":2744,"primaryCompletion":2723,"completion":2723,"start":624,"enrollment":2724,"conditions":2745,"interventions":2746},[64],[2726],[2709,2728],{"trials":2748,"activeCount":73},[],{"trials":2750,"activeCount":73},[],{"intervention":2752,"totalTrials":279,"cells":2753},"CD5789 (trifarotene) 50µg\u002Fg Cream",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2771,"NA":2773},{"trials":2755,"activeCount":73},[],{"trials":2757,"activeCount":73},[],{"trials":2759,"activeCount":73},[],{"trials":2761,"activeCount":73},[2762],{"nctId":2763,"briefTitle":2764,"status":79,"phases":2765,"primaryCompletion":2766,"completion":2767,"start":687,"enrollment":2768,"conditions":2769,"interventions":2770},"NCT02556788","Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg\u002Fg Cream Versus Vehicle Cream in Acne Vulgaris",[64],"2017-02-07","2017-05-12",1212,[15],[2752],{"trials":2772,"activeCount":73},[],{"trials":2774,"activeCount":73},[],{"intervention":2776,"totalTrials":279,"cells":2777},"CD5789",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2795,"NA":2797},{"trials":2779,"activeCount":73},[],{"trials":2781,"activeCount":73},[],{"trials":2783,"activeCount":73},[],{"trials":2785,"activeCount":73},[2786],{"nctId":2787,"briefTitle":2788,"status":79,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":2792,"conditions":2793,"interventions":2794},"NCT02189629","CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris",[64],"2017-02-23","2015-02-23",453,[15],[2776],{"trials":2796,"activeCount":73},[],{"trials":2798,"activeCount":73},[],{"intervention":2800,"totalTrials":279,"cells":2801},"Metvix and natural daylight PDT",{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2808,"PHASE4":2819,"NA":2821},{"trials":2803,"activeCount":73},[],{"trials":2805,"activeCount":73},[],{"trials":2807,"activeCount":73},[],{"trials":2809,"activeCount":73},[2810],{"nctId":2811,"briefTitle":2812,"status":79,"phases":2813,"primaryCompletion":2814,"completion":1430,"start":2815,"enrollment":756,"conditions":2816,"interventions":2817},"NCT01475071","Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses",[64],"2012-11","2012-03",[1785],[2800,2818],"Metvix and conventional PDT",{"trials":2820,"activeCount":73},[],{"trials":2822,"activeCount":73},[],{"intervention":2818,"totalTrials":279,"cells":2824},{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2837,"NA":2839},{"trials":2826,"activeCount":73},[],{"trials":2828,"activeCount":73},[],{"trials":2830,"activeCount":73},[],{"trials":2832,"activeCount":73},[2833],{"nctId":2811,"briefTitle":2812,"status":79,"phases":2834,"primaryCompletion":2814,"completion":1430,"start":2815,"enrollment":756,"conditions":2835,"interventions":2836},[64],[1785],[2800,2818],{"trials":2838,"activeCount":73},[],{"trials":2840,"activeCount":73},[],{"intervention":2842,"totalTrials":279,"cells":2843},"Adapalene BPO",{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2860,"NA":2862},{"trials":2845,"activeCount":73},[],{"trials":2847,"activeCount":73},[],{"trials":2849,"activeCount":73},[],{"trials":2851,"activeCount":73},[2852],{"nctId":2853,"briefTitle":2854,"status":79,"phases":2855,"primaryCompletion":348,"completion":348,"start":2856,"enrollment":2857,"conditions":2858,"interventions":2859},"NCT00441415","Efficacy and Safety of Fixed Combination Adapalene 0.1% \u002F Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris",[64],"2007-02",272,[15],[2842],{"trials":2861,"activeCount":73},[],{"trials":2863,"activeCount":73},[],{"intervention":538,"totalTrials":279,"cells":2865},{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2878,"NA":2880},{"trials":2867,"activeCount":73},[],{"trials":2869,"activeCount":73},[],{"trials":2871,"activeCount":73},[],{"trials":2873,"activeCount":73},[2874],{"nctId":530,"briefTitle":531,"status":79,"phases":2875,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":2876,"interventions":2877},[64],[399],[519,538],{"trials":2879,"activeCount":73},[],{"trials":2881,"activeCount":73},[],{"intervention":2883,"totalTrials":279,"cells":2884},"Metvix cream",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2891,"PHASE4":2901,"NA":2903},{"trials":2886,"activeCount":73},[],{"trials":2888,"activeCount":73},[],{"trials":2890,"activeCount":73},[],{"trials":2892,"activeCount":73},[2893],{"nctId":2894,"briefTitle":2895,"status":79,"phases":2896,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":1672,"conditions":2899,"interventions":2900},"NCT00472108","Photodynamic Therapy (PDT) With Metvix Cream 160 mg\u002Fg Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma",[64],"2002-04","2000-12",[2499],[2883],{"trials":2902,"activeCount":73},[],{"trials":2904,"activeCount":73},[],{"intervention":2906,"totalTrials":279,"cells":2907},"Adapalene BPO Gel standard daily overnight application",{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2914,"PHASE4":2926,"NA":2928},{"trials":2909,"activeCount":73},[],{"trials":2911,"activeCount":73},[],{"trials":2913,"activeCount":73},[],{"trials":2915,"activeCount":73},[2916],{"nctId":2917,"briefTitle":2918,"status":79,"phases":2919,"primaryCompletion":2920,"completion":2920,"start":659,"enrollment":502,"conditions":2921,"interventions":2922},"NCT00883233","Comparison of Four Different Regimens of Adapalene 0.1% \u002F Benzoyl Peroxide 2.5% Gel in Acne Vulgaris",[64],"2009-09",[21],[2906,2923,2924,2925],"Adapalene-BPO 3-hour daily application before bedtime","Adapalene-BPO Gel every other day application","Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion",{"trials":2927,"activeCount":73},[],{"trials":2929,"activeCount":73},[],{"intervention":2923,"totalTrials":279,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2944,"NA":2946},{"trials":2933,"activeCount":73},[],{"trials":2935,"activeCount":73},[],{"trials":2937,"activeCount":73},[],{"trials":2939,"activeCount":73},[2940],{"nctId":2917,"briefTitle":2918,"status":79,"phases":2941,"primaryCompletion":2920,"completion":2920,"start":659,"enrollment":502,"conditions":2942,"interventions":2943},[64],[21],[2906,2923,2924,2925],{"trials":2945,"activeCount":73},[],{"trials":2947,"activeCount":73},[],{"intervention":2924,"totalTrials":279,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2962,"NA":2964},{"trials":2951,"activeCount":73},[],{"trials":2953,"activeCount":73},[],{"trials":2955,"activeCount":73},[],{"trials":2957,"activeCount":73},[2958],{"nctId":2917,"briefTitle":2918,"status":79,"phases":2959,"primaryCompletion":2920,"completion":2920,"start":659,"enrollment":502,"conditions":2960,"interventions":2961},[64],[21],[2906,2923,2924,2925],{"trials":2963,"activeCount":73},[],{"trials":2965,"activeCount":73},[],{"intervention":2925,"totalTrials":279,"cells":2967},{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2974,"PHASE4":2980,"NA":2982},{"trials":2969,"activeCount":73},[],{"trials":2971,"activeCount":73},[],{"trials":2973,"activeCount":73},[],{"trials":2975,"activeCount":73},[2976],{"nctId":2917,"briefTitle":2918,"status":79,"phases":2977,"primaryCompletion":2920,"completion":2920,"start":659,"enrollment":502,"conditions":2978,"interventions":2979},[64],[21],[2906,2923,2924,2925],{"trials":2981,"activeCount":73},[],{"trials":2983,"activeCount":73},[],{"intervention":2985,"totalTrials":279,"cells":2986},"MAL 16.8% cream",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":3006,"NA":3008},{"trials":2988,"activeCount":73},[],{"trials":2990,"activeCount":73},[],{"trials":2992,"activeCount":73},[],{"trials":2994,"activeCount":73},[2995],{"nctId":2996,"briefTitle":2997,"status":79,"phases":2998,"primaryCompletion":2999,"completion":3000,"start":3001,"enrollment":3002,"conditions":3003,"interventions":3004},"NCT04085367","Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face",[64],"2021-03-03","2021-04-07","2019-09-30",557,[1785],[2985,3005],"MAL Vehicle Cream",{"trials":3007,"activeCount":73},[],{"trials":3009,"activeCount":73},[],{"intervention":3005,"totalTrials":279,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3018,"PHASE4":3024,"NA":3026},{"trials":3013,"activeCount":73},[],{"trials":3015,"activeCount":73},[],{"trials":3017,"activeCount":73},[],{"trials":3019,"activeCount":73},[3020],{"nctId":2996,"briefTitle":2997,"status":79,"phases":3021,"primaryCompletion":2999,"completion":3000,"start":3001,"enrollment":3002,"conditions":3022,"interventions":3023},[64],[1785],[2985,3005],{"trials":3025,"activeCount":73},[],{"trials":3027,"activeCount":73},[],{"intervention":749,"totalTrials":279,"cells":3029},{"EARLY_PHASE1":3030,"PHASE1":3032,"PHASE2":3034,"PHASE3":3036,"PHASE4":3042,"NA":3044},{"trials":3031,"activeCount":73},[],{"trials":3033,"activeCount":73},[],{"trials":3035,"activeCount":73},[],{"trials":3037,"activeCount":73},[3038],{"nctId":740,"briefTitle":741,"status":79,"phases":3039,"primaryCompletion":743,"completion":743,"start":744,"enrollment":745,"conditions":3040,"interventions":3041},[64],[747],[729,749],{"trials":3043,"activeCount":73},[],{"trials":3045,"activeCount":73},[],{"intervention":3047,"totalTrials":279,"cells":3048},"GK567",{"EARLY_PHASE1":3049,"PHASE1":3051,"PHASE2":3053,"PHASE3":3055,"PHASE4":3065,"NA":3067},{"trials":3050,"activeCount":73},[],{"trials":3052,"activeCount":73},[],{"trials":3054,"activeCount":73},[],{"trials":3056,"activeCount":73},[3057],{"nctId":3058,"briefTitle":3059,"status":79,"phases":3060,"primaryCompletion":2642,"completion":2642,"start":534,"enrollment":3061,"conditions":3062,"interventions":3064},"NCT01541930","An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours",[64],21,[3063],"Malodorous Infected Cutaneous Ulcer",[3047],{"trials":3066,"activeCount":73},[],{"trials":3068,"activeCount":73},[],{"intervention":342,"totalTrials":279,"cells":3070},{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3077,"PHASE4":3083,"NA":3085},{"trials":3072,"activeCount":73},[],{"trials":3074,"activeCount":73},[],{"trials":3076,"activeCount":73},[],{"trials":3078,"activeCount":73},[3079],{"nctId":333,"briefTitle":334,"status":79,"phases":3080,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":3081,"interventions":3082},[64],[15],[312,341,342,343],{"trials":3084,"activeCount":73},[],{"trials":3086,"activeCount":73},[],{"intervention":343,"totalTrials":279,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3095,"PHASE4":3101,"NA":3103},{"trials":3090,"activeCount":73},[],{"trials":3092,"activeCount":73},[],{"trials":3094,"activeCount":73},[],{"trials":3096,"activeCount":73},[3097],{"nctId":333,"briefTitle":334,"status":79,"phases":3098,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":3099,"interventions":3100},[64],[15],[312,341,342,343],{"trials":3102,"activeCount":73},[],{"trials":3104,"activeCount":73},[],{"intervention":3106,"totalTrials":279,"cells":3107},"Adapalene\u002F BPO gel with Lymecycline",{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3112,"PHASE3":3114,"PHASE4":3127,"NA":3129},{"trials":3109,"activeCount":73},[],{"trials":3111,"activeCount":73},[],{"trials":3113,"activeCount":73},[],{"trials":3115,"activeCount":73},[3116],{"nctId":3117,"briefTitle":3118,"status":79,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":3123,"conditions":3124,"interventions":3125},"NCT01014689","Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris",[64],"2010-04","2010-05","2009-08",378,[15],[3106,3126],"Adapalene\u002F BPO vehicle gel with Lymecycline",{"trials":3128,"activeCount":73},[],{"trials":3130,"activeCount":73},[],{"intervention":3126,"totalTrials":279,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":73},[],{"trials":3136,"activeCount":73},[],{"trials":3138,"activeCount":73},[],{"trials":3140,"activeCount":73},[3141],{"nctId":3117,"briefTitle":3118,"status":79,"phases":3142,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":3123,"conditions":3143,"interventions":3144},[64],[15],[3106,3126],{"trials":3146,"activeCount":73},[],{"trials":3148,"activeCount":73},[],{"intervention":581,"totalTrials":279,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3157,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":73},[],{"trials":3154,"activeCount":73},[],{"trials":3156,"activeCount":73},[],{"trials":3158,"activeCount":73},[3159],{"nctId":574,"briefTitle":575,"status":79,"phases":3160,"primaryCompletion":577,"completion":577,"start":386,"enrollment":578,"conditions":3161,"interventions":3162},[64],[15],[581,582,356],{"trials":3164,"activeCount":73},[],{"trials":3166,"activeCount":73},[],{"intervention":582,"totalTrials":279,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3181,"NA":3183},{"trials":3170,"activeCount":73},[],{"trials":3172,"activeCount":73},[],{"trials":3174,"activeCount":73},[],{"trials":3176,"activeCount":73},[3177],{"nctId":574,"briefTitle":575,"status":79,"phases":3178,"primaryCompletion":577,"completion":577,"start":386,"enrollment":578,"conditions":3179,"interventions":3180},[64],[15],[581,582,356],{"trials":3182,"activeCount":73},[],{"trials":3184,"activeCount":73},[],{"intervention":3186,"totalTrials":279,"cells":3187},"Epiduo\u002FTactuo",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3194,"PHASE4":3205,"NA":3207},{"trials":3189,"activeCount":73},[],{"trials":3191,"activeCount":73},[],{"trials":3193,"activeCount":73},[],{"trials":3195,"activeCount":73},[3196],{"nctId":3197,"briefTitle":3198,"status":79,"phases":3199,"primaryCompletion":386,"completion":387,"start":2383,"enrollment":3200,"conditions":3201,"interventions":3202},"NCT01474590","Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne",[64],266,[21],[3186,3203,3204],"doxycycline 200mg","Isotretinoin",{"trials":3206,"activeCount":73},[],{"trials":3208,"activeCount":73},[],{"intervention":3203,"totalTrials":279,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3217,"PHASE4":3223,"NA":3225},{"trials":3212,"activeCount":73},[],{"trials":3214,"activeCount":73},[],{"trials":3216,"activeCount":73},[],{"trials":3218,"activeCount":73},[3219],{"nctId":3197,"briefTitle":3198,"status":79,"phases":3220,"primaryCompletion":386,"completion":387,"start":2383,"enrollment":3200,"conditions":3221,"interventions":3222},[64],[21],[3186,3203,3204],{"trials":3224,"activeCount":73},[],{"trials":3226,"activeCount":73},[],{"intervention":3204,"totalTrials":279,"cells":3228},{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3235,"PHASE4":3241,"NA":3243},{"trials":3230,"activeCount":73},[],{"trials":3232,"activeCount":73},[],{"trials":3234,"activeCount":73},[],{"trials":3236,"activeCount":73},[3237],{"nctId":3197,"briefTitle":3198,"status":79,"phases":3238,"primaryCompletion":386,"completion":387,"start":2383,"enrollment":3200,"conditions":3239,"interventions":3240},[64],[21],[3186,3203,3204],{"trials":3242,"activeCount":73},[],{"trials":3244,"activeCount":73},[],{"intervention":3246,"totalTrials":279,"cells":3247},"clobetasol propionate shampoo",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3254,"PHASE4":3266,"NA":3268},{"trials":3249,"activeCount":73},[],{"trials":3251,"activeCount":73},[],{"trials":3253,"activeCount":73},[],{"trials":3255,"activeCount":73},[3256],{"nctId":3257,"briefTitle":3258,"status":79,"phases":3259,"primaryCompletion":2244,"completion":2244,"start":3260,"enrollment":3261,"conditions":3262,"interventions":3264},"NCT00862654","Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis",[64],"2009-03",326,[3263],"Scalp Seborrheic Dermatitis",[3246,3246,3246,3265],"ketoconazole shampoo",{"trials":3267,"activeCount":73},[],{"trials":3269,"activeCount":73},[],{"intervention":3265,"totalTrials":279,"cells":3271},{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3278,"PHASE4":3284,"NA":3286},{"trials":3273,"activeCount":73},[],{"trials":3275,"activeCount":73},[],{"trials":3277,"activeCount":73},[],{"trials":3279,"activeCount":73},[3280],{"nctId":3257,"briefTitle":3258,"status":79,"phases":3281,"primaryCompletion":2244,"completion":2244,"start":3260,"enrollment":3261,"conditions":3282,"interventions":3283},[64],[3263],[3246,3246,3246,3265],{"trials":3285,"activeCount":73},[],{"trials":3287,"activeCount":73},[],{"intervention":3289,"totalTrials":279,"cells":3290},"Nemolizumab 30 mg",{"EARLY_PHASE1":3291,"PHASE1":3293,"PHASE2":3295,"PHASE3":3297,"PHASE4":3308,"NA":3310},{"trials":3292,"activeCount":73},[],{"trials":3294,"activeCount":73},[],{"trials":3296,"activeCount":73},[],{"trials":3298,"activeCount":73},[3299],{"nctId":3300,"briefTitle":3301,"status":79,"phases":3302,"primaryCompletion":81,"completion":3303,"start":3304,"enrollment":3305,"conditions":3306,"interventions":3307},"NCT04501666","Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)",[64],"2023-02-21","2020-09-11",286,[32],[3289],{"trials":3309,"activeCount":73},[],{"trials":3311,"activeCount":73},[],{"intervention":3313,"totalTrials":279,"cells":3314},"Brimonidine tartrate was applied cutaneously once daily for 8 days.",{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3333,"NA":3335},{"trials":3316,"activeCount":73},[],{"trials":3318,"activeCount":73},[],{"trials":3320,"activeCount":73},[],{"trials":3322,"activeCount":73},[3323],{"nctId":3324,"briefTitle":3325,"status":79,"phases":3326,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":3329,"conditions":3330,"interventions":3331},"NCT01885000","Patient-Reported Outcome Of Facial Erythema (PROOF)",[64],"2013-11-14","2013-07-01",92,[18,2594],[3313,3332],"Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.",{"trials":3334,"activeCount":73},[],{"trials":3336,"activeCount":73},[],{"intervention":3332,"totalTrials":279,"cells":3338},{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3345,"PHASE4":3351,"NA":3353},{"trials":3340,"activeCount":73},[],{"trials":3342,"activeCount":73},[],{"trials":3344,"activeCount":73},[],{"trials":3346,"activeCount":73},[3347],{"nctId":3324,"briefTitle":3325,"status":79,"phases":3348,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":3329,"conditions":3349,"interventions":3350},[64],[18,2594],[3313,3332],{"trials":3352,"activeCount":73},[],{"trials":3354,"activeCount":73},[],{"intervention":2671,"totalTrials":279,"cells":3356},{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3363,"PHASE4":3369,"NA":3371},{"trials":3358,"activeCount":73},[],{"trials":3360,"activeCount":73},[],{"trials":3362,"activeCount":73},[],{"trials":3364,"activeCount":73},[3365],{"nctId":2664,"briefTitle":2665,"status":79,"phases":3366,"primaryCompletion":2667,"completion":2667,"start":577,"enrollment":2668,"conditions":3367,"interventions":3368},[64],[15],[2653,2671,2672],{"trials":3370,"activeCount":73},[],{"trials":3372,"activeCount":73},[],{"intervention":2672,"totalTrials":279,"cells":3374},{"EARLY_PHASE1":3375,"PHASE1":3377,"PHASE2":3379,"PHASE3":3381,"PHASE4":3387,"NA":3389},{"trials":3376,"activeCount":73},[],{"trials":3378,"activeCount":73},[],{"trials":3380,"activeCount":73},[],{"trials":3382,"activeCount":73},[3383],{"nctId":2664,"briefTitle":2665,"status":79,"phases":3384,"primaryCompletion":2667,"completion":2667,"start":577,"enrollment":2668,"conditions":3385,"interventions":3386},[64],[15],[2653,2671,2672],{"trials":3388,"activeCount":73},[],{"trials":3390,"activeCount":73},[],{"intervention":3392,"totalTrials":279,"cells":3393},"NDL-PDT",{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3400,"PHASE4":3411,"NA":3413},{"trials":3395,"activeCount":73},[],{"trials":3397,"activeCount":73},[],{"trials":3399,"activeCount":73},[],{"trials":3401,"activeCount":73},[3402],{"nctId":3403,"briefTitle":3404,"status":79,"phases":3405,"primaryCompletion":3406,"completion":577,"start":386,"enrollment":3407,"conditions":3408,"interventions":3409},"NCT01821391","Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses",[64],"2014-01",131,[1785],[3392,3410],"c-PDT",{"trials":3412,"activeCount":73},[],{"trials":3414,"activeCount":73},[],{"intervention":3410,"totalTrials":279,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3423,"PHASE4":3429,"NA":3431},{"trials":3418,"activeCount":73},[],{"trials":3420,"activeCount":73},[],{"trials":3422,"activeCount":73},[],{"trials":3424,"activeCount":73},[3425],{"nctId":3403,"briefTitle":3404,"status":79,"phases":3426,"primaryCompletion":3406,"completion":577,"start":386,"enrollment":3407,"conditions":3427,"interventions":3428},[64],[1785],[3392,3410],{"trials":3430,"activeCount":73},[],{"trials":3432,"activeCount":73},[],{"intervention":3434,"totalTrials":279,"cells":3435},"CD5789 (trifarotene) 50μg\u002Fg cream",{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3442,"PHASE4":3453,"NA":3455},{"trials":3437,"activeCount":73},[],{"trials":3439,"activeCount":73},[],{"trials":3441,"activeCount":73},[],{"trials":3443,"activeCount":73},[3444],{"nctId":3445,"briefTitle":3446,"status":79,"phases":3447,"primaryCompletion":3448,"completion":3448,"start":3449,"enrollment":3450,"conditions":3451,"interventions":3452},"NCT02566369","Efficacy and Safety of CD5789 (Trifarotene) 50μg\u002Fg Cream Versus Vehicle Cream in Acne Vulgaris",[64],"2017-11-14","2015-11-30",1208,[15],[3434],{"trials":3454,"activeCount":73},[],{"trials":3456,"activeCount":73},[],{"intervention":2422,"totalTrials":279,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3465,"PHASE4":3471,"NA":3473},{"trials":3460,"activeCount":73},[],{"trials":3462,"activeCount":73},[],{"trials":3464,"activeCount":73},[],{"trials":3466,"activeCount":73},[3467],{"nctId":2412,"briefTitle":2413,"status":79,"phases":3468,"primaryCompletion":2415,"completion":2416,"start":2417,"enrollment":2418,"conditions":3469,"interventions":3470},[64],[2420],[2401,2422],{"trials":3472,"activeCount":73},[],{"trials":3474,"activeCount":73},[],{"intervention":2646,"totalTrials":279,"cells":3476},{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3483,"PHASE4":3489,"NA":3491},{"trials":3478,"activeCount":73},[],{"trials":3480,"activeCount":73},[],{"trials":3482,"activeCount":73},[],{"trials":3484,"activeCount":73},[3485],{"nctId":2639,"briefTitle":2640,"status":79,"phases":3486,"primaryCompletion":1408,"completion":1408,"start":2642,"enrollment":2643,"conditions":3487,"interventions":3488},[64],[18],[2646,2647],{"trials":3490,"activeCount":73},[],{"trials":3492,"activeCount":73},[],{"intervention":3494,"totalTrials":279,"cells":3495},"Metvix-PDT",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3514,"NA":3516},{"trials":3497,"activeCount":73},[],{"trials":3499,"activeCount":73},[],{"trials":3501,"activeCount":73},[],{"trials":3503,"activeCount":73},[3504],{"nctId":3505,"briefTitle":3506,"status":79,"phases":3507,"primaryCompletion":3508,"completion":3508,"start":3509,"enrollment":3407,"conditions":3510,"interventions":3512},"NCT00304239","Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp",[64],"2007-01-23","2006-03-13",[3511],"Actinic Keratosis",[3494,3513],"Vehicle-PDT",{"trials":3515,"activeCount":73},[],{"trials":3517,"activeCount":73},[],{"intervention":3513,"totalTrials":279,"cells":3519},{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3526,"PHASE4":3532,"NA":3534},{"trials":3521,"activeCount":73},[],{"trials":3523,"activeCount":73},[],{"trials":3525,"activeCount":73},[],{"trials":3527,"activeCount":73},[3528],{"nctId":3505,"briefTitle":3506,"status":79,"phases":3529,"primaryCompletion":3508,"completion":3508,"start":3509,"enrollment":3407,"conditions":3530,"interventions":3531},[64],[3511],[3494,3513],{"trials":3533,"activeCount":73},[],{"trials":3535,"activeCount":73},[],{"intervention":3537,"totalTrials":279,"cells":3538},"Adapalene 0.3% \u002F BPO 2.5% gel",{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3555,"NA":3557},{"trials":3540,"activeCount":73},[],{"trials":3542,"activeCount":73},[],{"trials":3544,"activeCount":73},[],{"trials":3546,"activeCount":73},[3547],{"nctId":3548,"briefTitle":3549,"status":79,"phases":3550,"primaryCompletion":3551,"completion":3551,"start":3552,"enrollment":152,"conditions":3553,"interventions":3554},"NCT02932267","Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne",[64],"2018-01-10","2017-02-02",[15],[3537],{"trials":3556,"activeCount":73},[],{"trials":3558,"activeCount":73},[],{"intervention":3560,"totalTrials":279,"cells":3561},"C. propionate - Corticosteroid 1",{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3568,"PHASE4":3583,"NA":3585},{"trials":3563,"activeCount":73},[],{"trials":3565,"activeCount":73},[],{"trials":3567,"activeCount":73},[],{"trials":3569,"activeCount":73},[3570],{"nctId":3571,"briefTitle":3572,"status":79,"phases":3573,"primaryCompletion":1831,"completion":3574,"start":2856,"enrollment":3575,"conditions":3576,"interventions":3577},"NCT00438399","Subject Preference for Scalp Psoriasis Treatment",[64],"2008-02",219,[662],[3560,3578,3579,3580,3581,3582],"C. propionate- Corticosteroid 2","C. propionate -Corticosteroid 3","Corticosteroid 1- C. propionate","Corticosteroid 2 - C. propionate","Corticosteroid 3 - C. propionate",{"trials":3584,"activeCount":73},[],{"trials":3586,"activeCount":73},[],{"intervention":3578,"totalTrials":279,"cells":3588},{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3595,"PHASE4":3601,"NA":3603},{"trials":3590,"activeCount":73},[],{"trials":3592,"activeCount":73},[],{"trials":3594,"activeCount":73},[],{"trials":3596,"activeCount":73},[3597],{"nctId":3571,"briefTitle":3572,"status":79,"phases":3598,"primaryCompletion":1831,"completion":3574,"start":2856,"enrollment":3575,"conditions":3599,"interventions":3600},[64],[662],[3560,3578,3579,3580,3581,3582],{"trials":3602,"activeCount":73},[],{"trials":3604,"activeCount":73},[],{"intervention":3579,"totalTrials":279,"cells":3606},{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3619,"NA":3621},{"trials":3608,"activeCount":73},[],{"trials":3610,"activeCount":73},[],{"trials":3612,"activeCount":73},[],{"trials":3614,"activeCount":73},[3615],{"nctId":3571,"briefTitle":3572,"status":79,"phases":3616,"primaryCompletion":1831,"completion":3574,"start":2856,"enrollment":3575,"conditions":3617,"interventions":3618},[64],[662],[3560,3578,3579,3580,3581,3582],{"trials":3620,"activeCount":73},[],{"trials":3622,"activeCount":73},[],{"intervention":3580,"totalTrials":279,"cells":3624},{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3631,"PHASE4":3637,"NA":3639},{"trials":3626,"activeCount":73},[],{"trials":3628,"activeCount":73},[],{"trials":3630,"activeCount":73},[],{"trials":3632,"activeCount":73},[3633],{"nctId":3571,"briefTitle":3572,"status":79,"phases":3634,"primaryCompletion":1831,"completion":3574,"start":2856,"enrollment":3575,"conditions":3635,"interventions":3636},[64],[662],[3560,3578,3579,3580,3581,3582],{"trials":3638,"activeCount":73},[],{"trials":3640,"activeCount":73},[],{"intervention":3581,"totalTrials":279,"cells":3642},{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3647,"PHASE3":3649,"PHASE4":3655,"NA":3657},{"trials":3644,"activeCount":73},[],{"trials":3646,"activeCount":73},[],{"trials":3648,"activeCount":73},[],{"trials":3650,"activeCount":73},[3651],{"nctId":3571,"briefTitle":3572,"status":79,"phases":3652,"primaryCompletion":1831,"completion":3574,"start":2856,"enrollment":3575,"conditions":3653,"interventions":3654},[64],[662],[3560,3578,3579,3580,3581,3582],{"trials":3656,"activeCount":73},[],{"trials":3658,"activeCount":73},[],{"intervention":3582,"totalTrials":279,"cells":3660},{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3665,"PHASE3":3667,"PHASE4":3673,"NA":3675},{"trials":3662,"activeCount":73},[],{"trials":3664,"activeCount":73},[],{"trials":3666,"activeCount":73},[],{"trials":3668,"activeCount":73},[3669],{"nctId":3571,"briefTitle":3572,"status":79,"phases":3670,"primaryCompletion":1831,"completion":3574,"start":2856,"enrollment":3575,"conditions":3671,"interventions":3672},[64],[662],[3560,3578,3579,3580,3581,3582],{"trials":3674,"activeCount":73},[],{"trials":3676,"activeCount":73},[],{"intervention":278,"totalTrials":279,"cells":3678},{"EARLY_PHASE1":3679,"PHASE1":3681,"PHASE2":3683,"PHASE3":3685,"PHASE4":3691,"NA":3693},{"trials":3680,"activeCount":73},[],{"trials":3682,"activeCount":73},[],{"trials":3684,"activeCount":73},[],{"trials":3686,"activeCount":73},[3687],{"nctId":268,"briefTitle":269,"status":270,"phases":3688,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":3689,"interventions":3690},[64],[276],[278,236],{"trials":3692,"activeCount":73},[],{"trials":3694,"activeCount":73},[],{"intervention":3696,"totalTrials":279,"cells":3697},"Clobex® Shampoo",{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3704,"PHASE4":3716,"NA":3718},{"trials":3699,"activeCount":73},[],{"trials":3701,"activeCount":73},[],{"trials":3703,"activeCount":73},[],{"trials":3705,"activeCount":73},[3706],{"nctId":3707,"briefTitle":3708,"status":79,"phases":3709,"primaryCompletion":3710,"completion":3710,"start":3711,"enrollment":3712,"conditions":3713,"interventions":3714},"NCT00400725","Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis",[64],"2007-08-20","2006-09-29",288,[662],[3696,3715,3696],"Clobex® Vehicle Shampoo",{"trials":3717,"activeCount":73},[],{"trials":3719,"activeCount":73},[],{"intervention":3715,"totalTrials":279,"cells":3721},{"EARLY_PHASE1":3722,"PHASE1":3724,"PHASE2":3726,"PHASE3":3728,"PHASE4":3734,"NA":3736},{"trials":3723,"activeCount":73},[],{"trials":3725,"activeCount":73},[],{"trials":3727,"activeCount":73},[],{"trials":3729,"activeCount":73},[3730],{"nctId":3707,"briefTitle":3708,"status":79,"phases":3731,"primaryCompletion":3710,"completion":3710,"start":3711,"enrollment":3712,"conditions":3732,"interventions":3733},[64],[662],[3696,3715,3696],{"trials":3735,"activeCount":73},[],{"trials":3737,"activeCount":73},[],{"intervention":3739,"totalTrials":279,"cells":3740},"CD07805\u002F47 gel 0.5%\u002FCD07805\u002F47 Vehicle",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3747,"PHASE4":3756,"NA":3758},{"trials":3742,"activeCount":73},[],{"trials":3744,"activeCount":73},[],{"trials":3746,"activeCount":73},[],{"trials":3748,"activeCount":73},[3749],{"nctId":3750,"briefTitle":3751,"status":79,"phases":3752,"primaryCompletion":2642,"completion":2642,"start":607,"enrollment":1628,"conditions":3753,"interventions":3754},"NCT01659853","Efficacy and Safety Study Comparing CD07805\u002F47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea",[64],[2594,18],[3739,3755],"azelaic acid gel 15%",{"trials":3757,"activeCount":73},[],{"trials":3759,"activeCount":73},[],{"intervention":3755,"totalTrials":279,"cells":3761},{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3768,"PHASE4":3774,"NA":3776},{"trials":3763,"activeCount":73},[],{"trials":3765,"activeCount":73},[],{"trials":3767,"activeCount":73},[],{"trials":3769,"activeCount":73},[3770],{"nctId":3750,"briefTitle":3751,"status":79,"phases":3771,"primaryCompletion":2642,"completion":2642,"start":607,"enrollment":1628,"conditions":3772,"interventions":3773},[64],[2594,18],[3739,3755],{"trials":3775,"activeCount":73},[],{"trials":3777,"activeCount":73},[],{"intervention":453,"totalTrials":279,"cells":3779},{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3792,"NA":3794},{"trials":3781,"activeCount":73},[],{"trials":3783,"activeCount":73},[],{"trials":3785,"activeCount":73},[],{"trials":3787,"activeCount":73},[3788],{"nctId":445,"briefTitle":446,"status":79,"phases":3789,"primaryCompletion":448,"completion":448,"start":449,"enrollment":450,"conditions":3790,"interventions":3791},[64],[21],[453,423],{"trials":3793,"activeCount":73},[],{"trials":3795,"activeCount":73},[],{"intervention":3797,"totalTrials":156,"cells":3798},"AbobotulinumtoxinA dose 3",{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3828,"PHASE4":3830,"NA":3832},{"trials":3800,"activeCount":73},[],{"trials":3802,"activeCount":73},[],{"trials":3804,"activeCount":73},[3805,3816],{"nctId":3806,"briefTitle":3807,"status":79,"phases":3808,"primaryCompletion":171,"completion":3809,"start":3810,"enrollment":407,"conditions":3811,"interventions":3813},"NCT04080882","Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands",[63],"2020-06-04","2019-09-25",[3812],"Platysmal Bands",[3814,3815,3797],"AbobotulinumtoxinA dose 1","AbobotulinumtoxinA dose 2",{"nctId":3817,"briefTitle":3818,"status":79,"phases":3819,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":3824,"interventions":3825},"NCT03736928","Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines",[63],"2019-12-09","2020-08-20","2018-11-26",401,[24],[3826,3797,3827],"AbobotulinumtoxinA dose level 1 or 2","AbobotulinumtoxinA dose 4",{"trials":3829,"activeCount":73},[],{"trials":3831,"activeCount":73},[],{"trials":3833,"activeCount":73},[],{"intervention":3835,"totalTrials":156,"cells":3836},"CD 2027",{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3838,"activeCount":73},[],{"trials":3840,"activeCount":73},[],{"trials":3842,"activeCount":73},[3843,3851],{"nctId":3844,"briefTitle":3845,"status":79,"phases":3846,"primaryCompletion":646,"completion":3260,"start":1475,"enrollment":3847,"conditions":3848,"interventions":3849},"NCT00763555","Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis",[63],88,[35],[3835,3850],"Calcitriol Vehicle",{"nctId":3852,"briefTitle":3853,"status":79,"phases":3854,"primaryCompletion":1604,"completion":2723,"start":1475,"enrollment":1519,"conditions":3855,"interventions":3857},"NCT00763503","Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis",[63],[3856],"Plaque-type Psoriasis",[3835],{"trials":3859,"activeCount":73},[],{"trials":3861,"activeCount":73},[],{"trials":3863,"activeCount":73},[],{"intervention":3865,"totalTrials":156,"cells":3866},"Vehicle",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3868,"activeCount":73},[],{"trials":3870,"activeCount":73},[],{"trials":3872,"activeCount":73},[3873,3883],{"nctId":3874,"briefTitle":3875,"status":79,"phases":3876,"primaryCompletion":3877,"completion":3878,"start":3879,"enrollment":810,"conditions":3880,"interventions":3881},"NCT02995473","Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis",[63],"2018-05-03","2018-05-28","2017-02-08",[35],[3882,3865],"NP000888",{"nctId":3884,"briefTitle":3885,"status":79,"phases":3886,"primaryCompletion":2667,"completion":2667,"start":577,"enrollment":3887,"conditions":3888,"interventions":3889},"NCT02073461","Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.",[63],236,[15],[3890,3891,3865],"CD1579 2.5%","CD1579 5%",{"trials":3893,"activeCount":73},[],{"trials":3895,"activeCount":73},[],{"trials":3897,"activeCount":73},[],{"intervention":3899,"totalTrials":279,"cells":3900},"Epiduo vehicle gel",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3902,"activeCount":73},[],{"trials":3904,"activeCount":73},[],{"trials":3906,"activeCount":73},[3907],{"nctId":3908,"briefTitle":3909,"status":79,"phases":3910,"primaryCompletion":3911,"completion":3911,"start":3120,"enrollment":721,"conditions":3912,"interventions":3913},"NCT01106807","Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne",[63],"2010-09",[21],[3899,3914,3914,3915],"CD07223","Epiduo (adapalene and benzoyl peroxide) 0.1%\u002F2.5% gel",{"trials":3917,"activeCount":73},[],{"trials":3919,"activeCount":73},[],{"trials":3921,"activeCount":73},[],{"intervention":3914,"totalTrials":279,"cells":3923},{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3925,"activeCount":73},[],{"trials":3927,"activeCount":73},[],{"trials":3929,"activeCount":73},[3930],{"nctId":3908,"briefTitle":3909,"status":79,"phases":3931,"primaryCompletion":3911,"completion":3911,"start":3120,"enrollment":721,"conditions":3932,"interventions":3933},[63],[21],[3899,3914,3914,3915],{"trials":3935,"activeCount":73},[],{"trials":3937,"activeCount":73},[],{"trials":3939,"activeCount":73},[],{"intervention":3915,"totalTrials":279,"cells":3941},{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3946,"PHASE3":3952,"PHASE4":3954,"NA":3956},{"trials":3943,"activeCount":73},[],{"trials":3945,"activeCount":73},[],{"trials":3947,"activeCount":73},[3948],{"nctId":3908,"briefTitle":3909,"status":79,"phases":3949,"primaryCompletion":3911,"completion":3911,"start":3120,"enrollment":721,"conditions":3950,"interventions":3951},[63],[21],[3899,3914,3914,3915],{"trials":3953,"activeCount":73},[],{"trials":3955,"activeCount":73},[],{"trials":3957,"activeCount":73},[],{"intervention":254,"totalTrials":279,"cells":3959},{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3970,"PHASE4":3972,"NA":3974},{"trials":3961,"activeCount":73},[],{"trials":3963,"activeCount":73},[],{"trials":3965,"activeCount":73},[3966],{"nctId":245,"briefTitle":246,"status":79,"phases":3967,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":3968,"interventions":3969},[63],[15],[254,255,256,257,236],{"trials":3971,"activeCount":73},[],{"trials":3973,"activeCount":73},[],{"trials":3975,"activeCount":73},[],{"intervention":255,"totalTrials":279,"cells":3977},{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3988,"PHASE4":3990,"NA":3992},{"trials":3979,"activeCount":73},[],{"trials":3981,"activeCount":73},[],{"trials":3983,"activeCount":73},[3984],{"nctId":245,"briefTitle":246,"status":79,"phases":3985,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":3986,"interventions":3987},[63],[15],[254,255,256,257,236],{"trials":3989,"activeCount":73},[],{"trials":3991,"activeCount":73},[],{"trials":3993,"activeCount":73},[],{"intervention":256,"totalTrials":279,"cells":3995},{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4000,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":3997,"activeCount":73},[],{"trials":3999,"activeCount":73},[],{"trials":4001,"activeCount":73},[4002],{"nctId":245,"briefTitle":246,"status":79,"phases":4003,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":4004,"interventions":4005},[63],[15],[254,255,256,257,236],{"trials":4007,"activeCount":73},[],{"trials":4009,"activeCount":73},[],{"trials":4011,"activeCount":73},[],{"intervention":257,"totalTrials":279,"cells":4013},{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4018,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4015,"activeCount":73},[],{"trials":4017,"activeCount":73},[],{"trials":4019,"activeCount":73},[4020],{"nctId":245,"briefTitle":246,"status":79,"phases":4021,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":4022,"interventions":4023},[63],[15],[254,255,256,257,236],{"trials":4025,"activeCount":73},[],{"trials":4027,"activeCount":73},[],{"trials":4029,"activeCount":73},[],{"intervention":4031,"totalTrials":279,"cells":4032},"COL-101 (doxycycline, USP)",{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4037,"PHASE3":4048,"PHASE4":4050,"NA":4052},{"trials":4034,"activeCount":73},[],{"trials":4036,"activeCount":73},[],{"trials":4038,"activeCount":73},[4039],{"nctId":4040,"briefTitle":4041,"status":79,"phases":4042,"primaryCompletion":1603,"completion":448,"start":2266,"enrollment":1628,"conditions":4043,"interventions":4047},"NCT00560703","Treatment of Patients With Blepharitis and Facial Rosacea",[63],[4044,4045,4046],"Blepharitis","Meibomianitis","Dry Eye",[4031],{"trials":4049,"activeCount":73},[],{"trials":4051,"activeCount":73},[],{"trials":4053,"activeCount":73},[],{"intervention":4055,"totalTrials":279,"cells":4056},"0.18% COL-118 facial gel",{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4061,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4058,"activeCount":73},[],{"trials":4060,"activeCount":73},[],{"trials":4062,"activeCount":73},[4063],{"nctId":4064,"briefTitle":4065,"status":79,"phases":4066,"primaryCompletion":4067,"completion":4067,"start":625,"enrollment":145,"conditions":4068,"interventions":4070},"NCT00697541","Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%",[63],"2008-06",[4069],"Erythematous Rosacea",[4055,4071,4072,4073],"0.2% brimonidine ophthalmic solution","Advanced Eye Relief","COL-118 facial gel vehicle",{"trials":4075,"activeCount":73},[],{"trials":4077,"activeCount":73},[],{"trials":4079,"activeCount":73},[],{"intervention":4071,"totalTrials":279,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4083,"activeCount":73},[],{"trials":4085,"activeCount":73},[],{"trials":4087,"activeCount":73},[4088],{"nctId":4064,"briefTitle":4065,"status":79,"phases":4089,"primaryCompletion":4067,"completion":4067,"start":625,"enrollment":145,"conditions":4090,"interventions":4091},[63],[4069],[4055,4071,4072,4073],{"trials":4093,"activeCount":73},[],{"trials":4095,"activeCount":73},[],{"trials":4097,"activeCount":73},[],{"intervention":4072,"totalTrials":279,"cells":4099},{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4101,"activeCount":73},[],{"trials":4103,"activeCount":73},[],{"trials":4105,"activeCount":73},[4106],{"nctId":4064,"briefTitle":4065,"status":79,"phases":4107,"primaryCompletion":4067,"completion":4067,"start":625,"enrollment":145,"conditions":4108,"interventions":4109},[63],[4069],[4055,4071,4072,4073],{"trials":4111,"activeCount":73},[],{"trials":4113,"activeCount":73},[],{"trials":4115,"activeCount":73},[],{"intervention":4073,"totalTrials":279,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4119,"activeCount":73},[],{"trials":4121,"activeCount":73},[],{"trials":4123,"activeCount":73},[4124],{"nctId":4064,"briefTitle":4065,"status":79,"phases":4125,"primaryCompletion":4067,"completion":4067,"start":625,"enrollment":145,"conditions":4126,"interventions":4127},[63],[4069],[4055,4071,4072,4073],{"trials":4129,"activeCount":73},[],{"trials":4131,"activeCount":73},[],{"trials":4133,"activeCount":73},[],{"intervention":3814,"totalTrials":279,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4146,"PHASE4":4148,"NA":4150},{"trials":4137,"activeCount":73},[],{"trials":4139,"activeCount":73},[],{"trials":4141,"activeCount":73},[4142],{"nctId":3806,"briefTitle":3807,"status":79,"phases":4143,"primaryCompletion":171,"completion":3809,"start":3810,"enrollment":407,"conditions":4144,"interventions":4145},[63],[3812],[3814,3815,3797],{"trials":4147,"activeCount":73},[],{"trials":4149,"activeCount":73},[],{"trials":4151,"activeCount":73},[],{"intervention":3815,"totalTrials":279,"cells":4153},{"EARLY_PHASE1":4154,"PHASE1":4156,"PHASE2":4158,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4155,"activeCount":73},[],{"trials":4157,"activeCount":73},[],{"trials":4159,"activeCount":73},[4160],{"nctId":3806,"briefTitle":3807,"status":79,"phases":4161,"primaryCompletion":171,"completion":3809,"start":3810,"enrollment":407,"conditions":4162,"interventions":4163},[63],[3812],[3814,3815,3797],{"trials":4165,"activeCount":73},[],{"trials":4167,"activeCount":73},[],{"trials":4169,"activeCount":73},[],{"intervention":99,"totalTrials":279,"cells":4171},{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4176,"PHASE3":4182,"PHASE4":4184,"NA":4186},{"trials":4173,"activeCount":73},[],{"trials":4175,"activeCount":73},[],{"trials":4177,"activeCount":73},[4178],{"nctId":91,"briefTitle":92,"status":79,"phases":4179,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":4180,"interventions":4181},[63],[27],[41,99],{"trials":4183,"activeCount":73},[],{"trials":4185,"activeCount":73},[],{"trials":4187,"activeCount":73},[],{"intervention":4189,"totalTrials":279,"cells":4190},"CD07805\u002F47",{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4192,"activeCount":73},[],{"trials":4194,"activeCount":73},[],{"trials":4196,"activeCount":73},[4197],{"nctId":4198,"briefTitle":4199,"status":79,"phases":4200,"primaryCompletion":4201,"completion":658,"start":2920,"enrollment":1807,"conditions":4202,"interventions":4204},"NCT00989014","Dose-Finding Study of CD07805\u002F47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea",[63],"2009-11",[4203],"Erythematotelangiectatic Rosacea",[4189,4189,4189,4205],"CD07805\u002F47 placebo",{"trials":4207,"activeCount":73},[],{"trials":4209,"activeCount":73},[],{"trials":4211,"activeCount":73},[],{"intervention":4205,"totalTrials":279,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4224,"PHASE4":4226,"NA":4228},{"trials":4215,"activeCount":73},[],{"trials":4217,"activeCount":73},[],{"trials":4219,"activeCount":73},[4220],{"nctId":4198,"briefTitle":4199,"status":79,"phases":4221,"primaryCompletion":4201,"completion":658,"start":2920,"enrollment":1807,"conditions":4222,"interventions":4223},[63],[4203],[4189,4189,4189,4205],{"trials":4225,"activeCount":73},[],{"trials":4227,"activeCount":73},[],{"trials":4229,"activeCount":73},[],{"intervention":2558,"totalTrials":279,"cells":4231},{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4233,"activeCount":73},[],{"trials":4235,"activeCount":73},[],{"trials":4237,"activeCount":73},[4238],{"nctId":2551,"briefTitle":2552,"status":79,"phases":4239,"primaryCompletion":2554,"completion":2554,"start":2555,"enrollment":1628,"conditions":4240,"interventions":4241},[63],[32],[2558,224],{"trials":4243,"activeCount":73},[],{"trials":4245,"activeCount":73},[],{"trials":4247,"activeCount":73},[],{"intervention":4249,"totalTrials":279,"cells":4250},"Calcitriol 3mcg\u002Fg",{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4266,"PHASE4":4268,"NA":4270},{"trials":4252,"activeCount":73},[],{"trials":4254,"activeCount":73},[],{"trials":4256,"activeCount":73},[4257],{"nctId":4258,"briefTitle":4259,"status":79,"phases":4260,"primaryCompletion":4261,"completion":4261,"start":4262,"enrollment":2430,"conditions":4263,"interventions":4265},"NCT00419666","A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis",[63],"2009-09-24","2006-08-01",[4264],"Chronic Plaque Psoriasis",[4249],{"trials":4267,"activeCount":73},[],{"trials":4269,"activeCount":73},[],{"trials":4271,"activeCount":73},[],{"intervention":3850,"totalTrials":279,"cells":4273},{"EARLY_PHASE1":4274,"PHASE1":4276,"PHASE2":4278,"PHASE3":4284,"PHASE4":4286,"NA":4288},{"trials":4275,"activeCount":73},[],{"trials":4277,"activeCount":73},[],{"trials":4279,"activeCount":73},[4280],{"nctId":3844,"briefTitle":3845,"status":79,"phases":4281,"primaryCompletion":646,"completion":3260,"start":1475,"enrollment":3847,"conditions":4282,"interventions":4283},[63],[35],[3835,3850],{"trials":4285,"activeCount":73},[],{"trials":4287,"activeCount":73},[],{"trials":4289,"activeCount":73},[],{"intervention":4291,"totalTrials":279,"cells":4292},"CD2475\u002F101 40 mg",{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4297,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4294,"activeCount":73},[],{"trials":4296,"activeCount":73},[],{"trials":4298,"activeCount":73},[4299],{"nctId":4300,"briefTitle":4301,"status":79,"phases":4302,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4306,"interventions":4307},"NCT01320033","Placebo Controlled Efficacy and Safety Study of CD2475\u002F101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris",[63],"2012-01-03","2011-03-29",662,[15],[4291,4308],"Doxycycline 100 mg",{"trials":4310,"activeCount":73},[],{"trials":4312,"activeCount":73},[],{"trials":4314,"activeCount":73},[],{"intervention":4308,"totalTrials":279,"cells":4316},{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4318,"activeCount":73},[],{"trials":4320,"activeCount":73},[],{"trials":4322,"activeCount":73},[4323],{"nctId":4300,"briefTitle":4301,"status":79,"phases":4324,"primaryCompletion":4303,"completion":4303,"start":4304,"enrollment":4305,"conditions":4325,"interventions":4326},[63],[15],[4291,4308],{"trials":4328,"activeCount":73},[],{"trials":4330,"activeCount":73},[],{"trials":4332,"activeCount":73},[],{"intervention":4334,"totalTrials":279,"cells":4335},"CD11301 0.03%",{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4353,"PHASE4":4355,"NA":4357},{"trials":4337,"activeCount":73},[],{"trials":4339,"activeCount":73},[],{"trials":4341,"activeCount":73},[4342],{"nctId":4343,"briefTitle":4344,"status":79,"phases":4345,"primaryCompletion":4346,"completion":4346,"start":4347,"enrollment":4348,"conditions":4349,"interventions":4351},"NCT03292406","A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)",[63],"2020-03-17","2017-12-19",86,[4350],"Cutaneous T Cell Lymphoma",[4334,4352],"CD11301 0.06%",{"trials":4354,"activeCount":73},[],{"trials":4356,"activeCount":73},[],{"trials":4358,"activeCount":73},[],{"intervention":4352,"totalTrials":279,"cells":4360},{"EARLY_PHASE1":4361,"PHASE1":4363,"PHASE2":4365,"PHASE3":4371,"PHASE4":4373,"NA":4375},{"trials":4362,"activeCount":73},[],{"trials":4364,"activeCount":73},[],{"trials":4366,"activeCount":73},[4367],{"nctId":4343,"briefTitle":4344,"status":79,"phases":4368,"primaryCompletion":4346,"completion":4346,"start":4347,"enrollment":4348,"conditions":4369,"interventions":4370},[63],[4350],[4334,4352],{"trials":4372,"activeCount":73},[],{"trials":4374,"activeCount":73},[],{"trials":4376,"activeCount":73},[],{"intervention":3882,"totalTrials":279,"cells":4378},{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4383,"PHASE3":4389,"PHASE4":4391,"NA":4393},{"trials":4380,"activeCount":73},[],{"trials":4382,"activeCount":73},[],{"trials":4384,"activeCount":73},[4385],{"nctId":3874,"briefTitle":3875,"status":79,"phases":4386,"primaryCompletion":3877,"completion":3878,"start":3879,"enrollment":810,"conditions":4387,"interventions":4388},[63],[35],[3882,3865],{"trials":4390,"activeCount":73},[],{"trials":4392,"activeCount":73},[],{"trials":4394,"activeCount":73},[],{"intervention":4396,"totalTrials":279,"cells":4397},"CD07805\u002F47, CD07805\u002F47+Placebo, Placebo, CD07805\u002F47, Placebo",{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4402,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4399,"activeCount":73},[],{"trials":4401,"activeCount":73},[],{"trials":4403,"activeCount":73},[4404],{"nctId":4405,"briefTitle":4406,"status":79,"phases":4407,"primaryCompletion":4408,"completion":4408,"start":819,"enrollment":191,"conditions":4409,"interventions":4410},"NCT02300129","Effect of CD07805\u002F47 Gel in Rosacea Flushing",[63],"2014-06",[18],[4396,4411],"CD07805\u002F47, CD07805\u002F47+Placebo, Placebo, Placebo, CD07805\u002F47",{"trials":4413,"activeCount":73},[],{"trials":4415,"activeCount":73},[],{"trials":4417,"activeCount":73},[],{"intervention":4411,"totalTrials":279,"cells":4419},{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4421,"activeCount":73},[],{"trials":4423,"activeCount":73},[],{"trials":4425,"activeCount":73},[4426],{"nctId":4405,"briefTitle":4406,"status":79,"phases":4427,"primaryCompletion":4408,"completion":4408,"start":819,"enrollment":191,"conditions":4428,"interventions":4429},[63],[18],[4396,4411],{"trials":4431,"activeCount":73},[],{"trials":4433,"activeCount":73},[],{"trials":4435,"activeCount":73},[],{"intervention":4437,"totalTrials":279,"cells":4438},"CD5024 1% cream",{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4440,"activeCount":73},[],{"trials":4442,"activeCount":73},[],{"trials":4444,"activeCount":73},[4445],{"nctId":4446,"briefTitle":4447,"status":79,"phases":4448,"primaryCompletion":4449,"completion":4449,"start":4450,"enrollment":1628,"conditions":4451,"interventions":4452},"NCT03034460","Efficacy and Safety of CD5024 1% in Acne Vulgaris",[63],"2016-11-02","2016-04-25",[21],[4437,4453,4454,4455],"CD5024 cream placebo","CD0271\u002FCD1579 gel","CD0271\u002FCD1579 gel placebo",{"trials":4457,"activeCount":73},[],{"trials":4459,"activeCount":73},[],{"trials":4461,"activeCount":73},[],{"intervention":4453,"totalTrials":279,"cells":4463},{"EARLY_PHASE1":4464,"PHASE1":4466,"PHASE2":4468,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4465,"activeCount":73},[],{"trials":4467,"activeCount":73},[],{"trials":4469,"activeCount":73},[4470],{"nctId":4446,"briefTitle":4447,"status":79,"phases":4471,"primaryCompletion":4449,"completion":4449,"start":4450,"enrollment":1628,"conditions":4472,"interventions":4473},[63],[21],[4437,4453,4454,4455],{"trials":4475,"activeCount":73},[],{"trials":4477,"activeCount":73},[],{"trials":4479,"activeCount":73},[],{"intervention":4454,"totalTrials":279,"cells":4481},{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4486,"PHASE3":4492,"PHASE4":4494,"NA":4496},{"trials":4483,"activeCount":73},[],{"trials":4485,"activeCount":73},[],{"trials":4487,"activeCount":73},[4488],{"nctId":4446,"briefTitle":4447,"status":79,"phases":4489,"primaryCompletion":4449,"completion":4449,"start":4450,"enrollment":1628,"conditions":4490,"interventions":4491},[63],[21],[4437,4453,4454,4455],{"trials":4493,"activeCount":73},[],{"trials":4495,"activeCount":73},[],{"trials":4497,"activeCount":73},[],{"intervention":4455,"totalTrials":279,"cells":4499},{"EARLY_PHASE1":4500,"PHASE1":4502,"PHASE2":4504,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4501,"activeCount":73},[],{"trials":4503,"activeCount":73},[],{"trials":4505,"activeCount":73},[4506],{"nctId":4446,"briefTitle":4447,"status":79,"phases":4507,"primaryCompletion":4449,"completion":4449,"start":4450,"enrollment":1628,"conditions":4508,"interventions":4509},[63],[21],[4437,4453,4454,4455],{"trials":4511,"activeCount":73},[],{"trials":4513,"activeCount":73},[],{"trials":4515,"activeCount":73},[],{"intervention":3890,"totalTrials":279,"cells":4517},{"EARLY_PHASE1":4518,"PHASE1":4520,"PHASE2":4522,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4519,"activeCount":73},[],{"trials":4521,"activeCount":73},[],{"trials":4523,"activeCount":73},[4524],{"nctId":3884,"briefTitle":3885,"status":79,"phases":4525,"primaryCompletion":2667,"completion":2667,"start":577,"enrollment":3887,"conditions":4526,"interventions":4527},[63],[15],[3890,3891,3865],{"trials":4529,"activeCount":73},[],{"trials":4531,"activeCount":73},[],{"trials":4533,"activeCount":73},[],{"intervention":3891,"totalTrials":279,"cells":4535},{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4546,"PHASE4":4548,"NA":4550},{"trials":4537,"activeCount":73},[],{"trials":4539,"activeCount":73},[],{"trials":4541,"activeCount":73},[4542],{"nctId":3884,"briefTitle":3885,"status":79,"phases":4543,"primaryCompletion":2667,"completion":2667,"start":577,"enrollment":3887,"conditions":4544,"interventions":4545},[63],[15],[3890,3891,3865],{"trials":4547,"activeCount":73},[],{"trials":4549,"activeCount":73},[],{"trials":4551,"activeCount":73},[],{"intervention":4553,"totalTrials":279,"cells":4554},"Metvix Cream 160 mg\u002Fg",{"EARLY_PHASE1":4555,"PHASE1":4557,"PHASE2":4559,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4556,"activeCount":73},[],{"trials":4558,"activeCount":73},[],{"trials":4560,"activeCount":73},[4561],{"nctId":4562,"briefTitle":4563,"status":79,"phases":4564,"primaryCompletion":4565,"completion":4565,"start":4566,"enrollment":16,"conditions":4567,"interventions":4569},"NCT00437320","Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin",[63],"2008-09-01","2007-04-18",[4568],"Photoaged Skin",[4553,4570],"Metvix Vehicle Group",{"trials":4572,"activeCount":73},[],{"trials":4574,"activeCount":73},[],{"trials":4576,"activeCount":73},[],{"intervention":4570,"totalTrials":279,"cells":4578},{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4580,"activeCount":73},[],{"trials":4582,"activeCount":73},[],{"trials":4584,"activeCount":73},[4585],{"nctId":4562,"briefTitle":4563,"status":79,"phases":4586,"primaryCompletion":4565,"completion":4565,"start":4566,"enrollment":16,"conditions":4587,"interventions":4588},[63],[4568],[4553,4570],{"trials":4590,"activeCount":73},[],{"trials":4592,"activeCount":73},[],{"trials":4594,"activeCount":73},[],{"intervention":4596,"totalTrials":279,"cells":4597},"Botulinum Toxin Type A - Azzalure",{"EARLY_PHASE1":4598,"PHASE1":4600,"PHASE2":4602,"PHASE3":4612,"PHASE4":4614,"NA":4616},{"trials":4599,"activeCount":73},[],{"trials":4601,"activeCount":73},[],{"trials":4603,"activeCount":73},[4604],{"nctId":4605,"briefTitle":4606,"status":79,"phases":4607,"primaryCompletion":3120,"completion":3121,"start":448,"enrollment":745,"conditions":4608,"interventions":4610},"NCT01014871","Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles",[63],[4609],"Wrinkles",[4596,4611],"Botulinum Toxin Type A - Vistabel",{"trials":4613,"activeCount":73},[],{"trials":4615,"activeCount":73},[],{"trials":4617,"activeCount":73},[],{"intervention":4611,"totalTrials":279,"cells":4619},{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4630,"PHASE4":4632,"NA":4634},{"trials":4621,"activeCount":73},[],{"trials":4623,"activeCount":73},[],{"trials":4625,"activeCount":73},[4626],{"nctId":4605,"briefTitle":4606,"status":79,"phases":4627,"primaryCompletion":3120,"completion":3121,"start":448,"enrollment":745,"conditions":4628,"interventions":4629},[63],[4609],[4596,4611],{"trials":4631,"activeCount":73},[],{"trials":4633,"activeCount":73},[],{"trials":4635,"activeCount":73},[],{"intervention":4637,"totalTrials":279,"cells":4638},"CD2027 Ointment 3 mcg\u002Fg, twice daily",{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4643,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4640,"activeCount":73},[],{"trials":4642,"activeCount":73},[],{"trials":4644,"activeCount":73},[4645],{"nctId":4646,"briefTitle":4647,"status":79,"phases":4648,"primaryCompletion":4649,"completion":4649,"start":4650,"enrollment":2497,"conditions":4651,"interventions":4652},"NCT00919763","Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg\u002Fg) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis",[63],"2009-10-01","2009-05-21",[27],[4637,4653],"Vehicle Ointment, twice daily",{"trials":4655,"activeCount":73},[],{"trials":4657,"activeCount":73},[],{"trials":4659,"activeCount":73},[],{"intervention":4653,"totalTrials":279,"cells":4661},{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4666,"PHASE3":4672,"PHASE4":4674,"NA":4676},{"trials":4663,"activeCount":73},[],{"trials":4665,"activeCount":73},[],{"trials":4667,"activeCount":73},[4668],{"nctId":4646,"briefTitle":4647,"status":79,"phases":4669,"primaryCompletion":4649,"completion":4649,"start":4650,"enrollment":2497,"conditions":4670,"interventions":4671},[63],[27],[4637,4653],{"trials":4673,"activeCount":73},[],{"trials":4675,"activeCount":73},[],{"trials":4677,"activeCount":73},[],{"intervention":4679,"totalTrials":279,"cells":4680},"CD5024 0.3% cream",{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4685,"PHASE3":4696,"PHASE4":4698,"NA":4700},{"trials":4682,"activeCount":73},[],{"trials":4684,"activeCount":73},[],{"trials":4686,"activeCount":73},[4687],{"nctId":4688,"briefTitle":4689,"status":79,"phases":4690,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":4693,"conditions":4694,"interventions":4695},"NCT03250624","Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis",[63],"2017-06-26","2016-11-01",63,[27],[4679],{"trials":4697,"activeCount":73},[],{"trials":4699,"activeCount":73},[],{"trials":4701,"activeCount":73},[],{"intervention":4703,"totalTrials":279,"cells":4704},"CD10367 3% Solution - Non-desquamated zone",{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4724,"PHASE4":4726,"NA":4728},{"trials":4706,"activeCount":73},[],{"trials":4708,"activeCount":73},[],{"trials":4710,"activeCount":73},[4711],{"nctId":4712,"briefTitle":4713,"status":79,"phases":4714,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":1431,"conditions":4717,"interventions":4718},"NCT03025282","Safety and Efficacy of CD10367 in Psoriasis Vulgaris",[63],"2017-03-24","2016-11-03",[1207],[4703,4719,4720,4721,4722,4723],"CD10367 1% Solution - Non-desquamated zone","CD10367 solution placebo - Non-desquamated zone","Betneval ointment - Non-desquamated zone","CD10367 3% Solution - Desquamated zone","CD10367 solution placebo - Desquamated zone",{"trials":4725,"activeCount":73},[],{"trials":4727,"activeCount":73},[],{"trials":4729,"activeCount":73},[],{"intervention":4719,"totalTrials":279,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4742,"PHASE4":4744,"NA":4746},{"trials":4733,"activeCount":73},[],{"trials":4735,"activeCount":73},[],{"trials":4737,"activeCount":73},[4738],{"nctId":4712,"briefTitle":4713,"status":79,"phases":4739,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":1431,"conditions":4740,"interventions":4741},[63],[1207],[4703,4719,4720,4721,4722,4723],{"trials":4743,"activeCount":73},[],{"trials":4745,"activeCount":73},[],{"trials":4747,"activeCount":73},[],{"intervention":4720,"totalTrials":279,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4760,"PHASE4":4762,"NA":4764},{"trials":4751,"activeCount":73},[],{"trials":4753,"activeCount":73},[],{"trials":4755,"activeCount":73},[4756],{"nctId":4712,"briefTitle":4713,"status":79,"phases":4757,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":1431,"conditions":4758,"interventions":4759},[63],[1207],[4703,4719,4720,4721,4722,4723],{"trials":4761,"activeCount":73},[],{"trials":4763,"activeCount":73},[],{"trials":4765,"activeCount":73},[],{"intervention":4721,"totalTrials":279,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4769,"activeCount":73},[],{"trials":4771,"activeCount":73},[],{"trials":4773,"activeCount":73},[4774],{"nctId":4712,"briefTitle":4713,"status":79,"phases":4775,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":1431,"conditions":4776,"interventions":4777},[63],[1207],[4703,4719,4720,4721,4722,4723],{"trials":4779,"activeCount":73},[],{"trials":4781,"activeCount":73},[],{"trials":4783,"activeCount":73},[],{"intervention":4722,"totalTrials":279,"cells":4785},{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4787,"activeCount":73},[],{"trials":4789,"activeCount":73},[],{"trials":4791,"activeCount":73},[4792],{"nctId":4712,"briefTitle":4713,"status":79,"phases":4793,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":1431,"conditions":4794,"interventions":4795},[63],[1207],[4703,4719,4720,4721,4722,4723],{"trials":4797,"activeCount":73},[],{"trials":4799,"activeCount":73},[],{"trials":4801,"activeCount":73},[],{"intervention":4723,"totalTrials":279,"cells":4803},{"EARLY_PHASE1":4804,"PHASE1":4806,"PHASE2":4808,"PHASE3":4814,"PHASE4":4816,"NA":4818},{"trials":4805,"activeCount":73},[],{"trials":4807,"activeCount":73},[],{"trials":4809,"activeCount":73},[4810],{"nctId":4712,"briefTitle":4713,"status":79,"phases":4811,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":1431,"conditions":4812,"interventions":4813},[63],[1207],[4703,4719,4720,4721,4722,4723],{"trials":4815,"activeCount":73},[],{"trials":4817,"activeCount":73},[],{"trials":4819,"activeCount":73},[],{"intervention":3826,"totalTrials":279,"cells":4821},{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4823,"activeCount":73},[],{"trials":4825,"activeCount":73},[],{"trials":4827,"activeCount":73},[4828],{"nctId":3817,"briefTitle":3818,"status":79,"phases":4829,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":4830,"interventions":4831},[63],[24],[3826,3797,3827],{"trials":4833,"activeCount":73},[],{"trials":4835,"activeCount":73},[],{"trials":4837,"activeCount":73},[],{"intervention":3827,"totalTrials":279,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4850,"PHASE4":4852,"NA":4854},{"trials":4841,"activeCount":73},[],{"trials":4843,"activeCount":73},[],{"trials":4845,"activeCount":73},[4846],{"nctId":3817,"briefTitle":3818,"status":79,"phases":4847,"primaryCompletion":3820,"completion":3821,"start":3822,"enrollment":3823,"conditions":4848,"interventions":4849},[63],[24],[3826,3797,3827],{"trials":4851,"activeCount":73},[],{"trials":4853,"activeCount":73},[],{"trials":4855,"activeCount":73},[],{"intervention":2248,"totalTrials":279,"cells":4857},{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4866,"PHASE3":4868,"PHASE4":4870,"NA":4872},{"trials":4859,"activeCount":73},[],{"trials":4861,"activeCount":73},[4862],{"nctId":2241,"briefTitle":2242,"status":79,"phases":4863,"primaryCompletion":2244,"completion":2244,"start":743,"enrollment":2245,"conditions":4864,"interventions":4865},[62],[409],[2248,2249],{"trials":4867,"activeCount":73},[],{"trials":4869,"activeCount":73},[],{"trials":4871,"activeCount":73},[],{"trials":4873,"activeCount":73},[],{"intervention":4875,"totalTrials":279,"cells":4876},"METVIXIA Cream",{"EARLY_PHASE1":4877,"PHASE1":4879,"PHASE2":4889,"PHASE3":4891,"PHASE4":4893,"NA":4895},{"trials":4878,"activeCount":73},[],{"trials":4880,"activeCount":73},[4881],{"nctId":4882,"briefTitle":4883,"status":79,"phases":4884,"primaryCompletion":1204,"completion":1204,"start":1088,"enrollment":4885,"conditions":4886,"interventions":4888},"NCT02511145","Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration",[62],10,[4887],"Healthy",[4875],{"trials":4890,"activeCount":73},[],{"trials":4892,"activeCount":73},[],{"trials":4894,"activeCount":73},[],{"trials":4896,"activeCount":73},[],{"intervention":4898,"totalTrials":279,"cells":4899},"CD0271 0.1%\u002FCD1579 2.5% gel",{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4913,"PHASE3":4915,"PHASE4":4917,"NA":4919},{"trials":4901,"activeCount":73},[],{"trials":4903,"activeCount":73},[4904],{"nctId":4905,"briefTitle":4906,"status":79,"phases":4907,"primaryCompletion":4908,"completion":4908,"start":946,"enrollment":4909,"conditions":4910,"interventions":4911},"NCT01688531","A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients",[62],"2013-09",38,[21],[4898,4912],"CD0271 0.1%\u002FCD1579 2.5% gel vehicle",{"trials":4914,"activeCount":73},[],{"trials":4916,"activeCount":73},[],{"trials":4918,"activeCount":73},[],{"trials":4920,"activeCount":73},[],{"intervention":4912,"totalTrials":279,"cells":4922},{"EARLY_PHASE1":4923,"PHASE1":4925,"PHASE2":4931,"PHASE3":4933,"PHASE4":4935,"NA":4937},{"trials":4924,"activeCount":73},[],{"trials":4926,"activeCount":73},[4927],{"nctId":4905,"briefTitle":4906,"status":79,"phases":4928,"primaryCompletion":4908,"completion":4908,"start":946,"enrollment":4909,"conditions":4929,"interventions":4930},[62],[21],[4898,4912],{"trials":4932,"activeCount":73},[],{"trials":4934,"activeCount":73},[],{"trials":4936,"activeCount":73},[],{"trials":4938,"activeCount":73},[],{"intervention":2257,"totalTrials":279,"cells":4940},{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4949,"PHASE3":4951,"PHASE4":4953,"NA":4955},{"trials":4942,"activeCount":73},[],{"trials":4944,"activeCount":73},[4945],{"nctId":2251,"briefTitle":2252,"status":79,"phases":4946,"primaryCompletion":2244,"completion":2244,"start":743,"enrollment":2254,"conditions":4947,"interventions":4948},[62],[409],[2257,2249],{"trials":4950,"activeCount":73},[],{"trials":4952,"activeCount":73},[],{"trials":4954,"activeCount":73},[],{"trials":4956,"activeCount":73},[],{"intervention":4958,"totalTrials":11,"cells":4959},"AbobotulinumtoxinA",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4966,"PHASE4":4978,"NA":4989},{"trials":4961,"activeCount":73},[],{"trials":4963,"activeCount":73},[],{"trials":4965,"activeCount":73},[],{"trials":4967,"activeCount":73},[4968],{"nctId":4969,"briefTitle":4970,"status":79,"phases":4971,"primaryCompletion":4972,"completion":4973,"start":4974,"enrollment":4975,"conditions":4976,"interventions":4977},"NCT03960957","Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines",[64],"2019-09-27","2020-04-16","2019-06-17",301,[24],[4958],{"trials":4979,"activeCount":73},[4980],{"nctId":4981,"briefTitle":4982,"status":79,"phases":4983,"primaryCompletion":4984,"completion":4985,"start":4986,"enrollment":2487,"conditions":4987,"interventions":4988},"NCT03687736","Subject Satisfaction With AbobutulinumtoxinA Treatment",[65],"2019-11-07","2019-12-04","2018-10-02",[24],[4958],{"trials":4990,"activeCount":73},[4991],{"nctId":4992,"briefTitle":4993,"status":79,"phases":4994,"primaryCompletion":4995,"completion":4996,"start":4997,"enrollment":1981,"conditions":4998,"interventions":4999},"NCT05089357","Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin",[],"2023-09-12","2023-12-24","2021-11-11",[2525],[4958],{"intervention":1810,"totalTrials":156,"cells":5001},{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5006,"PHASE3":5008,"PHASE4":5010,"NA":5016},{"trials":5003,"activeCount":73},[],{"trials":5005,"activeCount":73},[],{"trials":5007,"activeCount":73},[],{"trials":5009,"activeCount":73},[],{"trials":5011,"activeCount":73},[5012],{"nctId":1803,"briefTitle":1804,"status":79,"phases":5013,"primaryCompletion":1806,"completion":1806,"start":1518,"enrollment":1807,"conditions":5014,"interventions":5015},[65],[30],[1810,1790],{"trials":5017,"activeCount":73},[5018],{"nctId":5019,"briefTitle":5020,"status":79,"phases":5021,"primaryCompletion":5022,"completion":5022,"start":783,"enrollment":5023,"conditions":5024,"interventions":5025},"NCT00437216","Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis",[],"2006-07",2488,[35],[1810,5026],"Clobetasol propionate, 0.05% Spray",{"intervention":5028,"totalTrials":279,"cells":5029},"Treatment: Minoxidil 2% \u002F Botanical Hair Solution for Women",{"EARLY_PHASE1":5030,"PHASE1":5032,"PHASE2":5034,"PHASE3":5036,"PHASE4":5038,"NA":5040},{"trials":5031,"activeCount":73},[],{"trials":5033,"activeCount":73},[],{"trials":5035,"activeCount":73},[],{"trials":5037,"activeCount":73},[],{"trials":5039,"activeCount":73},[],{"trials":5041,"activeCount":73},[5042],{"nctId":5043,"briefTitle":5044,"status":79,"phases":5045,"primaryCompletion":5046,"completion":5046,"start":5047,"enrollment":810,"conditions":5048,"interventions":5050},"NCT02460497","Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss\u002FAndrogenic Alopecia",[66],"2015-09-19","2015-05-27",[5049],"Female Pattern Hair Loss, Androgenic Alopecia",[5028],{"intervention":5052,"totalTrials":279,"cells":5053},"Sculptra and Alastin Restorative Skin Complex",{"EARLY_PHASE1":5054,"PHASE1":5056,"PHASE2":5058,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5055,"activeCount":73},[],{"trials":5057,"activeCount":73},[],{"trials":5059,"activeCount":73},[],{"trials":5061,"activeCount":73},[],{"trials":5063,"activeCount":73},[],{"trials":5065,"activeCount":73},[5066],{"nctId":5067,"briefTitle":5068,"status":79,"phases":5069,"primaryCompletion":5070,"completion":5070,"start":133,"enrollment":3061,"conditions":5071,"interventions":5074},"NCT05963204","A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator with a Skincare Regimen",[66],"2024-03-19",[5072,5073],"Photodamaged Skin","Volume Deficiency of the Midface",[5052,5075],"Sculptra and CeraVe Daily Moisturizing Lotion",{"intervention":5075,"totalTrials":279,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5086,"NA":5088},{"trials":5079,"activeCount":73},[],{"trials":5081,"activeCount":73},[],{"trials":5083,"activeCount":73},[],{"trials":5085,"activeCount":73},[],{"trials":5087,"activeCount":73},[],{"trials":5089,"activeCount":73},[5090],{"nctId":5067,"briefTitle":5068,"status":79,"phases":5091,"primaryCompletion":5070,"completion":5070,"start":133,"enrollment":3061,"conditions":5092,"interventions":5093},[66],[5072,5073],[5052,5075],{"intervention":5095,"totalTrials":279,"cells":5096},"Treatment: Minoxidil 5% \u002F Botanical Hair Solution for Men",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5101,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5098,"activeCount":73},[],{"trials":5100,"activeCount":73},[],{"trials":5102,"activeCount":73},[],{"trials":5104,"activeCount":73},[],{"trials":5106,"activeCount":73},[],{"trials":5108,"activeCount":73},[5109],{"nctId":5110,"briefTitle":5111,"status":79,"phases":5112,"primaryCompletion":687,"completion":687,"start":5113,"enrollment":4693,"conditions":5114,"interventions":5116},"NCT02460289","Minoxidil 5% \u002F Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss\u002FAndrogenic Alopecia",[66],"2015-05-19",[5115],"Male Pattern of Hair Loss, Androgenic Alopecia",[5095],{"intervention":5118,"totalTrials":279,"cells":5119},"Metvix",{"EARLY_PHASE1":5120,"PHASE1":5122,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5121,"activeCount":73},[],{"trials":5123,"activeCount":73},[],{"trials":5125,"activeCount":73},[],{"trials":5127,"activeCount":73},[],{"trials":5129,"activeCount":73},[],{"trials":5131,"activeCount":73},[5132],{"nctId":5133,"briefTitle":5134,"status":5135,"phases":5136,"conditions":5137,"interventions":5140},"NCT00535080","Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large\u002FMultiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease","NO_LONGER_AVAILABLE",[],[5138,2499,5139],"Field Actinic Keratoses","Bowen's Disease",[5118],{"intervention":5026,"totalTrials":279,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5149,"PHASE4":5151,"NA":5153},{"trials":5144,"activeCount":73},[],{"trials":5146,"activeCount":73},[],{"trials":5148,"activeCount":73},[],{"trials":5150,"activeCount":73},[],{"trials":5152,"activeCount":73},[],{"trials":5154,"activeCount":73},[5155],{"nctId":5019,"briefTitle":5020,"status":79,"phases":5156,"primaryCompletion":5022,"completion":5022,"start":783,"enrollment":5023,"conditions":5157,"interventions":5158},[],[35],[1810,5026],{"intervention":5160,"totalTrials":279,"cells":5161},"Metronidazole Gel",{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5168,"PHASE4":5170,"NA":5172},{"trials":5163,"activeCount":73},[],{"trials":5165,"activeCount":73},[],{"trials":5167,"activeCount":73},[],{"trials":5169,"activeCount":73},[],{"trials":5171,"activeCount":73},[],{"trials":5173,"activeCount":73},[5174],{"nctId":5175,"briefTitle":5176,"status":79,"phases":5177,"primaryCompletion":647,"completion":647,"start":3574,"enrollment":745,"conditions":5178,"interventions":5179},"NCT00668655","An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%",[],[18],[5160]]